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Abstract 
The gut microbiota plays an important role in the development of type 2 
diabetes (T2D), which is an alteration in the diversity and abundance of the gut 
microbiota, favouring the growth of Gram-negative bacteria. Although a lot of 
studies have shown this to be the case, most of this work has been done in animal 
models with few studies in humans. In animal models of T2D, it is known that a 
high-fat diet alters the gut microbiota in favour of the growth of Gram–negative 
bacteria. The outer membrane of Gram-negative bacteria contains 
lipopolysaccharide (LPS) which is an endotoxin that can trigger inflammation 
leading to metabolic disorders such insulin resistance and T2D, hence T2D is 
considered a low grade inflammatory disorder. 
In this thesis, the effect of Galactooligosaccharide (GOS), a prebiotic, on 
the composition of the gut microbiota was investigated. Next generation 
sequencing (NGS) of the gut microbiota of T2D and healthy control subjects 
showed no significant difference at the phylum level between the two groups. 
Furthermore, T2D patients in the prebiotic group had a significant increase in 
the level of Firmicutes compared to the placebo group. Also, although not 
significant, T2D patients on metformin had increased level of Bacteroidetes, 
Proteobacteria and Actinobacteria compared to those not on metformin. The 
ability of human faecal water (FW) to distinguish between healthy and T2D 
patients using an in vitro model of the intestinal mucosa was studied. FW from 
T2D patients decreased Caco-2 cell monolayer integrity when compared to the 
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healthy controls and in the T2D patients, FW activity in vitro correlated with 
biological markers of T2D severity measured in vivo. Additionally, cytokines were 
measured in T2D faecal samples using a human cytokine array. Finally, GOS 
anti-cytotoxic activity was also assessed in vitro using cell viability assays and 
the anti-cytotoxic effect of GOS was time and concentration dependent.  
Together, the thesis explored potential new ways of using faecal samples 
as biomarker for T2D in vitro and relating it to in vivo parameters of the 
patients. Also future work in this area may reveal mechanistic insight to the use 
of FW as a non-invasive biomarker for T2D. 
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INTRODUCTION 
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1. Introduction 
1.1. Diabetes Mellitus 
1.1.1. Overview 
Diabetes mellitus is a metabolic disease associated with by hyperglycaemia 
arising from defects in insulin secretion, insulin action, or both [1, 2]. All forms of 
diabetes are associated with substantial co-morbidity with the associated costs 
for both the individual patient and the NHS. In the UK, the total cost of direct 
patient care for diabetes in 2010 ⁄ 2011 is estimated at £9.8 billion, while the 
indirect costs associated with diabetes are estimated at £13.9 billion. The cost of 
screening, diagnosis, treatment, interventions and complications management 
accounts for over £2 billion of the direct cost. For complications experienced by 
those with Type 1 or Type 2 diabetes, the cost was estimated at £7.7 billion. It is 
projected that the cost will range between £13.8 billion and £20 billion by year 
2035 ⁄ 2036 [3, 4]. 
The severe and repeated hyperglycaemia of diabetes is associated with 
damage, dysfunction, and failure of multiple organs, especially the kidneys, eyes, 
heart, nerves and blood vessels [1, 5]. Moreover, diabetes can result in long-term 
complications such as retinopathy with potential loss of vision; peripheral 
neuropathy with risk of foot ulcers, amputations, and Charcot joints; autonomic 
neuropathy causing gastrointestinal, genitourinary, and cardiovascular 
symptoms; and nephropathy leading to renal failure. Furthermore, diabetic 
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patients have an increased incidence of atherosclerotic cardiovascular, 
cerebrovascular and peripheral arterial disease [1, 5]. In addition, abnormalities 
of lipoprotein metabolism and hypertension are also associated with diabetes [1, 
2]. 
The two most common forms of diabetes are type 1 Diabetes (T1D) and 
type 2 Diabetes (T2D). Other common types of diabetes include gestational and 
maturity onset of disease in the young (MODY) [1, 5]. T1D occurs when there is 
an absolute deficiency of insulin secretion and accounts for 5–10% of cases was 
historically referred to as insulin-dependent diabetes or juvenile-onset diabetes 
[1, 5]. This type of diabetes is an autoimmune condition and people at risk of 
development of T1D are usually identified by an autoimmune pathologic process 
occurring in the pancreatic islets and by genetic markers [1, 5]. T2D is a 
combination of resistance to insulin action which finally leads to an inadequate 
insulin secretion [1, 2, 5]. It accounts for 90–95% of cases and was historically 
known as non–insulin dependent diabetes or adult-onset diabetes [1, 2, 6]. These 
terms are no longer in common usage due to the number of patients with T2D 
who will eventually move onto insulin treatment, and with the age of onset of 
T2D now considerably younger than in previous generations. Although, a degree 
of hyperglycaemia enough to cause pathologic and functional changes in various 
target tissues may be present, there is often no clinical symptoms other than 
those associated with changes in plasma osmolarity (thirst, frequent urination) 
and the condition may be undetected for a long period of time [1, 2]. However, it 
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can be detected by measurement of plasma glucose in the fasting state or after an 
oral glucose load challenge, which demonstrates an abnormality in carbohydrate 
metabolism [1, 2].  
 
1.1.2. Epidemiology  
Factors such as population growth, age, urbanization, and increased 
prevalence of obesity and physical inactivity are leading to an increase incidence 
of diabetes [7]. Since approximately 1 in 22 people worldwide have diabetes, it is 
necessary to understand the aetiology of diabetes, now and in the future, to allow 
rational planning and allocation of resources[7]. In 2010, it was estimated that 
285 million adults had diabetes, which was 67% higher than the published 
estimate in 2004 [8]. In 2015, approximately 415 million adults have diabetes and 
it is estimated that the number of people with diabetes will further increase by 
2030 and 2040 to approximately 439 million and 642 million, respectively. The 
World health organisations (WHO) also projected that by 2030, diabetes will be 
the seventh leading cause of death [9]. 
Although the overall prevalence of diabetes prevalence is similar in men 
and women, its prevalence is slightly higher in men under 60 years of age and in 
women at older ages (over 65 years). Also, it is estimates that 90 percent of people 
around the world who have diabetes have type 2. In the least developed countries, 
the majority of people with diabetes are between 45- to 64-years of age while in 
developed countries majority of the people are 64 years of age or older [7]. It is 
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estimated that by 2030, the number of people with diabetes over 64 years of age 
will be greater than 82 and 48 million in the least developed and developed 
countries respectively, [7].  
This represents a mean annual increment of 20,000 cases [8]. In the UK, 
the Figures (Fig 1.1, 1.2, and 1.3) below represents the data for diabetes 
prevalence in both women and men for year 2014, projection and probability of 
halting the increase of diabetes by 2025 [11]. 
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Figure 1-1: A sunburst plot showing the number of adults with diabetes in 
High -income English speaking countries 
 7 
In the UK, 1.78million women and 2.06 million men have diabetes which 
accounts for 12.6% and 12.9% of the total population of women in the region, 
respectively [11] . 
 
 
Figure 1-2: World map showing projection of the prevalence of diabetes for adults 18 years 
and older, in different countries by 2025 
It is projected by 2025, the prevalence of diabetes will be 5.4% for women and 7.8% for men 
in the UK [11].
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Figure 1-3: World map showing probability of achieving the target of halting the rise in 
diabetes by 2025 compared to its 2010 level if post 2000 trends continues. 
In the UK, the probability is estimated at 48.4 % for women and 35.6% for men [11]. 
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1.1.3. Pathogenesis 
T2D is defined by an increasing decline in pancreatic beta cell function and 
chronic insulin resistance [1, 5, 12]. One major risk factor for the development of 
T2D is obesity although most people who are obese do not develop diabetes. T2D 
is a highly heterogeneous disorder but can be inherited, which accounts for about 
50% of the disease susceptibility [5, 13]. Over 40 diabetes-associated loci have 
been identified, most of which are associated with impaired β-cell function. Also 
gene defects that affect islet β-cell function are most common in patients with the 
monogenic form of the disease [5, 14].  
The islet β cells are sensitive to nutrient induced damage and play a vital 
role in the development of T2D [5, 13]. They maintain the synthesis of proinsulin 
with correct post- translational modification; affect the secretion of secretory 
granules; monitor nutrient concentrations in blood, usually by intracellular 
metabolism and production of nutrient-secretion coupling factors; and the release 
of insulin granule by activation of a complex exocytosis machinery [5, 15, 16]. 
However, in human T2D, islet β cells have the tendency to develop islet amyloid 
polypeptide and triglyceride deposits, and whilst this may not initiate the 
disease, it may contribute towards disease progression [5, 17]. Although it is 
difficult to identify the reasons for the failure of the beta cells, it is possible that a 
combination of β-cell susceptibility factors causes the initial mechanism of 
damage. Likewise, the development of severe hyperglycaemia leads to glucotoxic 
and gluco-lipotoxic activity which further affects the rate of failure [5, 18-20].  
 10 
Insulin resistance may induce abnormalities in adipose tissue which could 
occur independently from β-cell impairment [5, 21]. Healthy white adipose tissue 
protects against metabolic disease and acts as a fatty acid “sink” preventing the 
uptake and storage in ectopic tissues. In T2D, adipose tissue function may be 
compromised in many ways such as reduced rates of adipocyte differentiation and 
adipogenesis, reduced adiponectin expression and secretion, increased expression 
and secretion of inflammatory cytokines (e.g. tumour necrosis factor α, 
interleukin-1β, and monocyte-chemo-attractant protein-1) and increased tissue 
inflammation (e.g. macrophage infiltrates) . Impaired secretion of adiponectin 
and increased non-esterified fatty acids and concentration of inflammatory 
cytokines can aggravate insulin resistance in muscle and cause pathology in non-
alcoholic steatohepatitis [5, 15]  
In the liver, increased endogenous glucose production is a major 
determinant of fasting hyperglycaemia in T2D and is considered to be one of the 
earliest detectable defects in the condition [15, 17]. The production of glucose is 
not suppressed by insulin in the postprandial state and this contributes to a fed-
state hyperglycaemia. The mechanism that explains this is varied and complex 
but includes increased supply of gluconeogenic substrate from peripheral tissues, 
the hepatic response to raised concentrations of glucagon, and activation of 
hepatic gluconeogenesis by raised concentrations of non-esterified fatty acids [5, 
22, 23].  
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1.2. Treatment of Type 2 Diabetes 
1.2.1. Metformin 
Metformin belongs to the biguanide class of antidiabetes drugs and it is an 
orally administered drug. It is used for lowering blood glucose concentrations in 
patients with T2D, particularly in those overweight and obese as well as those 
with normal renal function [24-26]. The origin of biguanides can be traced from 
the use the plant Gallega officinalis, which was traditionally used in medieval 
Europe as a drug treatment for diabetes for centuries. The synthesis of galegine-
like compound called Guanidine derived from the plant led to the discovery of 
metformin [10, 16].The other two biguanides, phenformin and buformin, were 
withdrawn in the early 1970s due to the risk of lactic acidosis and increased 
cardiac mortality The usefulness of metformin was discovered in 1950 when it 
was observed to reduce glucose levels in a dose-response manner [13, 27, 28]. 
The mode of action is primarily at the liver where glucose output is 
reduced and aiding the uptake of glucose in the peripheral tissues, especially 
muscles [10, 16]. Metformin indirectly regulates and inactivates the downstream 
kinase adenosine monophosphate co-activator and transducers of regulated 
CREB protein 2 (TORC2) by activation of an upstream kinase, liver kinase B1 
(LKB-1). This results in downregulation of transcriptional events that promotes 
the synthesis of gluconeogenic enzyme [29-31]. Other than glycaemic control, 
metformin has an effect on inflammatory pathway [4, 16], endothelial function 
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[18], blood pressure [19], cancer [20] and most recently, the gut microbiota [21, 
22]. 
Metformin is the most prescribed drug by doctors for patients with T2D 
due to its efficacy, safety profile and beneficial metabolic and cardiovascular 
effects. It is the first line treatment based on the National institute for Health 
and Care Excellence (NICE) guidelines [29, 32-35]. To support this, in the UK 
primary care, a total of 8,838,031 individuals with T2D aged 0-99 years were 
included in a retrospective cohort study between 2000 and 2013. In 2000, 45.1% 
of T2D patients were administered metformin and it increased gradually on an 
annual basis to 91.0% for newly diagnosed T2D patients and 79.9 % of add-on 
therapy for patients on sulfonylureas by 2013 [36]. Furthermore, in 2005, 8.6 
million metformin hydrochloride drug were dispensed, and this increased to 18.1 
million items dispensed in 2014. This accounts for a 101.5% increase in 9 years, 
hence the leading anti-diabetic medicine used in the UK [37]. 
Metformin can also be given in combination with sulfonylureas, glinides, 
insulin, thiazolidinediones (TZD), alpha-glucosidase inhibitors, glucagon-like 
peptide-1 receptor agonist (RA-GLP1), sodium-glucose co-transporter 2 inhibitors 
(iSGLT2) and dipeptidylpeptidase 4 inhibitors (iDPP4). However adverse side 
effects have been associated with the use of metformin [38, 39]. The most 
commonly reported side effect is gastrointestinal intolerance which occurs in the 
form of anorexia, abdominal pain, flatulence and diarrhoea [31, 34, 39]. Although 
these effects subside once the dose is reduced or when administered with meal, 
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about 5% of patients do not tolerate metformin even at the lowest dose [38-40] 
and many others simply learn to tolerate the side-effects. 
Metformin (50-60%) is absorbed mainly from the small intestine and g ets 
into to the blood in about 1-2 hours after an oral dose of 500-1000mg [32]. The 
maximal plasma concentration is 1-2µg per millilitre and it remains in the blood 
for about 1.5 to 4.9 hours [32]. Metformin (approximately 90%) is eliminated in 
urine in 12 hours unchanged as no metabolites have been found in urine [32].  
 
1.3. Normal microbiota – Diabetes/obesity  
The human body is colonised on every surface that is exposed to the 
external environment by microorganisms. This includes the skin, respiratory, 
oral cavity, urogenital and gastrointestinal tract [41]. However, a large and 
varied population of microorganism inhabit the human large intestine including 
bacteria, fungi and archaea. Many of the microorganisms are beneficial to the 
host; however given the correct conditions some have been linked to clinical 
diseases [41, 42] . These microorganisms are collectively referred to as the gut 
microbiota [41]. 
The gut microbiota as a community consists of over 1500 species of 
microorganism with about 40 trillion bacterial cells in a human body [41, 43]. The 
Gram-positive bacteria are able to ferment undigested dietary polysaccharides 
such as dietary fibre and resistant starch to short chain fatty acids which are 
absorbed by the host and serves as energy [41]. Additional sources of substrates 
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to Gram-positive bacteria are provided by the host including desquamated 
epithelial cells, mucins and digestive enzymes [44]. Intestinal microbiota also aid 
in the conversion of secondary plant metabolites such as polyphenols in fruits, 
vegetables, cereals, chocolate, tea, coffee, or wine and glucosinolates in brassica 
vegetables. In addition, intestinal bacteria also play a role in the conversion of 
bile acids and metabolism of xenobiotics. Bile acids (cholic acid and 
chenodeoxycholic acid in humans) are synthesised in the liver, conjugated with 
either glycine or taurine and then secreted into the intestinal tract, where they 
undergo deconjugation and partial dehydroxylation by intestinal bacteria. While, 
xenobiotics are oxidised and subsequently sulphated or glucuronidated to render 
them water soluble and thereby facilitate their urinary excretion [45-49]. Also, 
the gut microbiota is able to synthesize vitamins such as vitamin B12, vitamin K, 
and folic acid and protects its host against the harmful effect of pathogenic 
bacteria. Furthermore, commensal gut microbiota also plays a role in maturation 
of immune cells and normal development of immune function [50, 51]. 
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Figure 1-4: The independent and dependent effect of the gut microbiota on host metabolism 
The independent effect of the gut microbiota results in the production of pro-inflammatory 
molecules, such as lipopolysaccharide and peptidoglycan, which may affect host metabolism 
through proteins produced by the host to mediate the immune response. While the dependent 
effect involves the metabolism of Choline, cholesterol and polysaccharides obtained from the diet 
by the gut microbiota and either directly or through further host–microbial co-metabolization 
generate bioactive compounds. In the case of choline, this can lead to cardiovascular disease; for 
cholesterol, activation of TGR5 can increase energy expenditure and GLP-1 secretion or protection 
against heart disease; and for polysaccharides, short-chain fatty acids can be used as an energy 
source or can bind to GPR41 or GPR43 to regulate hormones and modulate inflammation. FMO, 
flavin-containing monooxygenase; TLR4, Toll-like receptor 4; TMA, trimethylamine; TMAO, 
trimethylamine-N-oxide Reproduced from [49, 52]. 
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The human gut consists of bacteria groups belonging to 5 major phyla ; the 
Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and Verrucomicrobia 
[43]. The Firmicutes contain the genera lactobacillus which includes several 
strains of probiotics, butyrate producers such as Eubacterium, Feacalibacterium, 
Roseburia, Ruminococcus and Clostridium [43, 44]. The Bacteroidetes contains 
the genera Bacteroides, Prevotella and Xylanibacter. The Actinobacteria phylum 
contains Bifidobacteria (probiotic strains) and Collinsella. Proteobacteria phylum 
contains Desulfovibrio, which constitutes sulphate reducing bacteria and 
Escherichia from the Enterobacteriaceae family. Verrucomicrobia phylum 
contains Akkermansia which is known for mucus degradation [43].The phyla 
Firmicutes and Bacteroidetes constitute over 90% of the bacteria in the gut [53]. 
The beneficial intestinal microflora includes bifidobacteria and Lactobacilli [42]. 
Although most adults carry bifidobacteria in their colon, it is found mostly in the 
faeces of breast-fed infants [54-56]. This is a major pointer to the benefit of 
bifidobacteria to its host and the need to increase its population in the colon of 
adults. In adults, the Firmicutes and Bacteroidetes dominate the gut and it is 
stable over a long period of time [42, 54, 55]. 
Gut microbiota varies between individuals due to factors such as host 
genotype, age and geographical location [56-59]. Eventhough gut microbiota are 
shared among family members, there still exists, a variation in bacterial lineages 
[60] . This was shown in a study where characterization of the gut microbial 
communities in 31 monozygotic twin pairs, 23 dizygotic twin pairs and, where 
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available, their mothers, showed that the gut microbe was similar among family 
members but with a variation in the gut microbial community of specific bacterial 
lineages present in each person [60]. The gut microbial community of the adult 
monozygotic and dizygotic twin pairs showed variation with a comparable degree 
but there was a vast array of microbial genes shared among sampled individuals 
[60]. This may indicate that no two people have exact microbiota. 
 
1.4. Development and function dysbiosis in obesity and diabetes  
In both animal and human models, several studies have shown that 
alteration in the composition and activity of the gut microbiota may play a role in 
the development of T2D and obesity. This alteration is known as dysbiosis [51, 
61-64]. In mice, high levels of Bifidobacteria in the gut have been shown to 
improve intestinal permeability and reduce intestinal endotoxin levels [67, 69]. 
However, the genus Bifidobacterium belongs to the phylum Actinobacteria, which 
is found mostly in infants than adults and may be outnumbered by other bacteria 
[39]. In the human gut, the two major phyla are the Firmicutes and Bacteroidetes 
and the former and latter are composed mostly of Gram-positive and Gram-
negative bacteria, respectively [39]. The level of these phyla has been shown to 
differ in obesity and T2D. In obesity, the phylum Firmicutes is reported to be 
higher than the phylum Bacteroidetes. The level of Firmicutes are proposed to be 
the reason for weight gain in obesity because of the ability of the bacteria to 
reduce the fermentation of polysaccharides [82-84]. One of the principal end 
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products of colonic fermentation are SCFA, which are more in overweight/obese 
individuals’ faecal samples. This may be due to increased SCFA production, 
decreased SCFA absorption or fewer microbial species that utilize SCFA as an 
energy source in the obese microbiota. SCFA produced account for 5–10% of total 
dietary energy [85]. In lean and overweight/ obese individuals, the level of 
Firmicutes and Firmicutes/Bacteroidetes ratio was higher in the overweight/ 
obese than lean individuals. Also, faecal SCFA was higher in the latter than 
former. This difference was due to change in colonic microbiota and not dietary 
intake or SCFA absorption. This was evident in the study as Firmicutes and not 
fat intake positively correlated to faecal SCFA [86]. Contrary, In T2D, the 
phylum Bacteroidetes (contains mostly Gram-negative bacteria) is higher 
compared to the phylum Firmicutes [87, 88].  
Factors such as diet, intake of prebiotics, probiotics and antibiotics are 
thought to affect the gut microbiota [65-67], as well as the host immune functions 
[68-70] in T2D and obesity. Although T2D and obesity are now considered as low 
grade inflammation conditions, the exact mechanism through which this occurs is 
unknown. However, from several animal model studies, it is hypothesised that 
high-fat diet feeding leads to altered gut microbiota, and then the translocation of 
LPS or whole bacteria into the blood is followed by metabolic endotoxaemia and 
onset of metabolic disorders [71-76]. However, why high fat foods change the gut 
microbiota and result in the onset of metabolic disorders is unknown. It could be 
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possible that some diets promote the growth of Gram-positive bacteria while 
other diets could promote the growth of Gram- negative bacteria [77]. 
 
 
Figure 1-5: The hallmarks of obesity, metabolic syndrome and diabetes 
High-fat/ high–glycaemic load diet in hyperglycaemia (HG) and increased free 
fatty acids (FFA), could result in increased activation of the inflammasome 
complex as well as increase the activation of macrophages via increased TLR 
activation and NF-κB activation. Also the diet can cause changes to the gut 
microbiota by altering the content of histidine, glutamate, SCFAs, and other 
factors and promote gut barrier dysfunction and conditions prevalent in obesity, 
metabolic syndrome, and diabetes by altering the host response Adapted from 
[51]. 
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1.5. Prebiotic Concepts: Animal models and Human Studies 
Prebiotics are defined as “a non-digestible food ingredient that beneficially 
affects the host by selectively stimulating the growth and/or activity of one or a 
limited number of bacteria in the colon and thus improves host health.”[78] 
However, the effects of prebiotics in the colon are not permanent and disappear 
from faeces few days after oral dose is stopped [42].In contrast, probiotics are live 
organisms that when ingested in sufficient amounts confers a health benefit to 
the host. Several supplements containing viable microorganisms with probiotic 
properties are available commercially [79]. The commonly used probiotics are 
bifidobacteria, lactobacilli, and non-pathogenic yeasts.  
The human breast milk contains oligosaccharides, which is referred to as 
human milk oligosaccharides (HMOs) and are described as the prototypic 
prebiotic [80, 81]. In the colon of exclusively breast-fed neonates, they facilitate 
the preferential growth of bifidobacteria and lactobacilli, which may be a strong 
reason for some of the immunological and other benefits observed in breast-fed 
infants [80]. Prebiotics are not digested in the small intestine due to their 
chemical structure (they are considered under the Codex definition of dietary 
fibre), but are fermented in the colon [79, 80]. The endogenous bacteria ferment 
prebiotics to energy and metabolic substrates, with lactic and short-chain 
carboxylic acids as end products of the fermentation [79]. The current prebiotics 
in use are carbohydrates, which cannot be easily digested, present naturally in 
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food, but increasingly taken by the consumer as either a supplement or found 
fortified within a range of foodstuffs. These include galactooligosaccharides 
(GOS), mannooligosaccharides (MOS), pectic-oligosaccharides (POS), 
transgalactosylatedoligosaccharides (TOS), chitooligosaccharides and 
xylooligosaccharides (XOS) [79, 80]. The two commonly used prebiotics in most 
studies are inulin and oligofructose (FOS), however, the prebiotic property of 
GOS is becoming established with some efficacy demonstrated in healthy humans 
[42, 82, 83]. 
 
1.5.1. Galactooligosaccaride (GOS) 
GOS is produced by the enzymatic transgalactosylation of lactose using β-
galactosidase (lactase, EC 3.2.1; 2.4), forming several oligomers of different chain 
lengths, between DP2 to DP10 with a terminal glucose [81]. Whey-derived lactose 
is the primary raw material for the commercial production of GOS and it is 
formed in large amounts as a by-product of the dairy industry [80] . Furthermore, 
GOS can be produced using β-galactosidases of microbial sources in the forms of 
crude enzymes, purified enzymes, recombinant enzymes, immobilized enzymes, 
immobilized cells, toluene treated cells, and whole-cell biotransformation [80, 84]. 
Bifidobacteria and lactobacilli are termed ‘generally recognized as safe’ for use in 
food applications, hence they are of interest to many researchers as regards their 
enzymes for GOS production [84] This is because it is mostly likely to selectively 
 22 
promote the growth and metabolic activity of these bacterial genera in the gut, 
which will have health benefits to the host [80] [84, 85]. 
GOS has good moisture retention, highly soluble and has only about one 
third of the sweetness of sucrose. The molecules are highly stable in acidic 
conditions, room and high temperature conditions and this makes it easy to be 
incorporated into a wide variety of foods [80, 81]. In food, they have a pleasant 
taste, improve the texture and mouth-feel of foods, and act as bulking agents. 
GOS are used in a wide range of commercial products, including infant formulas, 
dairy products, soups, sauces, breakfast cereals, beverages, animal feeds, and as 
sugar replacements [80] . The fact that GOSs are synthesized from milk sugar 
and traditional dairy foods makes it ‘generally recognized as safe’ (GRAS). 
However, consumption of GOS at high levels has adverse effects of transient 
osmotic diarrhoea and flatulence [80]. 
 
1.5.2. Relevant studies on the efficacy of prebiotics 
Since the gut microflora attached to the gut mucosa (e.g. bifidobacteria) 
acts as barriers preventing the invasion of pathogenic bacteria, it is important 
that nutrients that can promote their growth are provided. Oligosaccharides such 
as well studied FOS, GOS, inulin and the disaccharides lactulose have been used 
as prebiotics in human and mice studies to remodel the gut microbiota [80, 86, 
87]. These carbohydrates are fermented by gut bacteria (e.g. bifidobacteria) for 
growth and these bacteria can competitively inhibit the growth of pathogenic 
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bacteria by reducing the luminal pH from an alkaline to acidic environment and 
the production of mucins and antibiotics is stimulated [88]. 
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1.5.2.1. Animal Studies using prebiotics  
Table 1-1: Example of Animal Studies (diabetes/obesity) designed to determine the prebiotic effect of inulin and oligofructose  
Subjects Component Dose Time Main outcomes Ref. 
Diabetic 
C57BL6/J Mice 
Oligofructose 
90:10 wt/wt 
(HF-OFS) 
14 weeks 
- Improved blood glucose 
- Normalised endotoxaemia 
- Normalised plasma and adipose tissue 
proinflammatory cytokines 
- Restore bifidobacteria 
[72] 
Obese JCR:LA-
cp rats 
Inulin and 
Oligofructose 
20% wt/wt 
 
10 weeks 
- Bacteroidetes decreased 
- Firmicutes,Bifidobacteria and lactobacilli 
increased 
 [89] 
Obese fa/fa Zuc
ker rats 
 10g 10 weeks 
- Slowed the increase in body weight 
- Decreased food intake 
- Lower glycemia 
- Phospholipemia, triglyceridemia and 
cholesterolemia remained unchanged 
- Lessen severe hepatic steatosis 
 [90] 
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Subjects Component Dose Time Main outcomes Ref. 
Diabetic 
C57BL6/J Mice 
Oligofructose 
90:10 wt/wt 
(HF-OFS) 
4 weeks 
- Improved glucose tolerance and fasting 
blood glucose  
- Improved glucose-stimulated insulin 
secretion, and insulin-sensitive hepatic 
glucose production  
- Reduces hepatic phosphorylation of IKK-β 
and NFκ-B  
- Reduced body weight gain 
[91] 
Pubs 
Inulin and 
oligofructose 
1:1 wt/wt 6 weeks 
- Increased mass of the small intestine, 
colon and cecum  
- Decreased glucose and increased GLP-1 
[92] 
Naïve Mice 
Native chicory 
Inulin 
 3 weeks 
- Reduced sucrase activity in the small 
intestine mucosa  
- Higher caecal content and tissue weight  
- No changes in body weight gain, fat mass 
or liver weight  
- No shift between bacterial phyla 
- Higher abundance of Lachnospiraceae and 
decreased abundance of vadin BB60 and 
Ruminococcaceae 
[93] 
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1.5.2.2. Relevant studies on the efficacy of prebiotics 
Human Studies using prebiotics 
The following studies illustrate the benefits of prebiotics such as 
oligofructose (FOS), galacto-oligosaccharides (GOS), and inulin. The benefits 
included changes in gut microbiota composition, improved immune function, 
metabolic biomarkers and anthropometric parameters. In a study where healthy 
men and women fed with FOS showed that satiety was increased after breakfast 
and dinner, hunger was reduced and food intake following dinner was reduced 
[94] . Another study of the effects of GOS on the composition of the human faecal 
microbiota in healthy adults showed that GOS increased the level of 
bifidobacteria species in half of the subjects at a magnitude of five- to ten-fold. 
Accordingly, increased Firmicutes was observed only in few subjects and decrease 
in Bacteroidetes as the bifidobacteria increased in the subjects [95]. The above 
findings are indicators that prebiotic feeding could be used to improve the 
composition of the gut microbiota, and reduce host susceptibility to diseases 
caused by pathogenic bacteria.  
The efficacy of oligofructose enriched inulin on reducing inflammatory 
cytokines and increasing anti-inflammatory cytokines in T2D was determined. 
The study included 70 females with T2D in a double-blinded placebo –controlled 
trial. The participants were between 30-65 years old, had T2D for more than 
6months and BMI between 25 and 34.99 kg/m2. Participants were allocated 
randomly into prebiotic treated and placebo group. The prebiotic treated group 
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had a daily intake of 10g oligofructose enriched inulin for two months, which 
resulted in a significant increase in anti-inflammatory cytokine IL-4 and 
reduction in inflammatory cytokine IL-12 and IFNγ , thereby improving the 
immune system in patients with T2D. Also, BMI, waist circumference, hip 
circumference, serum lipid, fasting serum glucose, HbA1c and diastolic blood 
pressure were improved in the prebiotic treated group. However, no significant 
change was observed for cell count of CD3+, CD4+, CD8+ and CD 11b+T after 
prebiotic treatment. In conclusion, this study highlighted the benefits of 
oligofructose enriched inulin on the improvement of immune function, glycaemic 
status and serum lipid, although underlying mechanism still needs to be 
investigated [96]. 
Another study using females with T2D between ages 30-65 years, assessed 
the effect of resistant dextrin as a prebiotic to improve insulin resistance and 
inflammation. The randomised controlled clinical trial included 30 and 25 
patients in the intervention and control group respectively and had 10g per day 
(5grams each during breakfast and dinner) of resistant dextrin in the 
intervention group or maltodextrin as placebo for 8weeks. The authors reported 
no significant baseline change for body weight and BMI between the two groups 
but significant decrease was observed after 8weeks supplementation in the 
resistant dextrin group when compared with those at baseline. Also, the resistant 
dextrin group had significant decrease in total fat and intakes of energy 
compared with those at baseline, but not significantly decreased in the 
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maltodextrin group. The glycaemic status did not differ significantly between the 
two groups at baseline but at the end of the trial, the resistant dextrin group had 
a significant decrease in fasting insulin concentration, quantitative insulin 
sensitivity check index, HOMA-IR, IL-6, TNFα, malondialdehyde, and endotoxin. 
However, the levels of fasting plasma glucose, HbA1c and hs-CRP, were not 
significantly reduced between the two groups. The findings reported in this study 
supports the conclusion that resistant dextrin supplementation can efficiently 
improve insulin resistance and inflammation in women with T2D [97]. 
 
1.6. Tight Junction and Intestinal Permeability 
The body’s largest interface with the external environment is the 
gastrointestinal epithelium. The epithelium primarily forms the intestinal 
barrier, with the individual epithelial cell membranes forming majority of the 
barrier. Its function is to allow the absorption of nutrients and provide a physical 
barrier to the translocation of pathogens, toxins and antigens which are pro-
inflammatory from the luminal environment into the mucosal tissues and 
circulatory system [71].The barrier are impermeable where specific transporters 
exist. Also the barrier can be severely compromised when epithelial cells are lost, 
as seen in erosions and ulcerations[98]. 
Selective permeability by the epithelial cells is created by two pathways: 
the transcellular and paracellular pathway [71]. Transcellular transport is 
dependent on cell-specific profile of transporters and channels positioned on the 
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apical and basolateral cell membranes. Also, it is directional and energy 
dependent. Paracellular transport is passive and results from diffusion, 
electrodiffusion, or osmosis down the gradients created by transcellular 
mechanisms. In contrast to transcellular transport, paracellular route is non-
directional, shows small differences in ionic selectivities and it varies extensively 
among epithelia in terms of electrical resistance. Thus, by defining the degree 
and selectivity of back leak for ions and solutes, the paracellular pathway 
complements transcellular mechanisms [99] 
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Figure 1-6: Transepithelial transport pathways 
The transcellular route is both active and passive. It is also based on the activity of 
transmembrane pumps, channels, and carriers expressed in a polarized fashion. However, 
paracellular transport is only passive and driven by the gradients secondary to 
transcellular transport mechanisms. The important barrier in the paracellular route is 
the tight junction, and it is regulated and varies among epithelia in tightness and ion 
selectivity. This regulated back diffusion can significantly modify the molecular 
composition of transcellular transport [99]. 
 
One of the apical junctional complexes that regulate the paracellular 
pathway is known as tight junctions [71]. The paracellular space between 
adjacent cells, would provide barrier function only where it is sealed by tight 
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junctions, which is most critical. An important factor for paracellular transit is 
the permeability of the tight junction that defines the overall barrier function of 
an intact intestinal epithelium. Tight junctions, also known as desmosomes, are 
composed of transmembrane proteins such as claudins and occludins [100]. Tight 
junctions determine the selective paracellular permeability to solutes and 
provides barrier to harmful molecules [98, 101]. Although pro-inflammatory 
cytokines, antigens and pathogens contribute to barrier impairment under 
pathophysiological conditions, other factors such as food and nutrients can modify 
tight junctions’ barrier functions and paracellular permeability which is 
associated with health and susceptibility diseases [102, 103]. Food consumed can 
either have beneficial or adverse effect on intestinal microbiota which also 
determines the “leakiness” of the gastrointestinal mucosa. However, the 
intestinal barrier function can also be improved by several protective measures 
such as antioxidants, epidermal growth factor, enteral feeding, fibre and oats, 
probiotics and trefoils [102]. 
 
1.7. High-fat diet, gut microbiota, impaired intestinal permeability and type 2 
diabetes 
A link between high-fat diet, gut microbiota, impaired tight junction and 
T2D has been established in several mice and human studies [71, 74, 104, 105] 
which have been shown to be LPS dependent [72-75]. A change in the gut 
microbiota may result in impaired intestinal permeability which is commonly 
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referred to as ‘leaky gut’ thereby increasing the concentrations of endotoxins such 
as LPS in the circulation in the blood [74] . The reduced expression of tight 
junction proteins such as ZO-1 and Occludin leads to increased intestinal 
permeability [74]. Several studies has also revealed that increased plasma 
concentration of bacterial LPS during a fat –enriched diet was responsible for the 
onset of metabolic endotoxaemia [71, 74, 75]. 
The importance of bacteria population in the onset of metabolic disorders 
has been studied in both animal and human models. A previous study using 
animal models of obesity, showed that compared to the control mice, obese mice 
fed prebiotic carbohydrates had increased Bifibobacteria spp., Lactobacillus spp. 
and Clostridium coccoides-Eubacterium rectale in the caecum. These species were 
linked to reduced gut permeability and lower level of LPS measured in vivo [106]. 
This was due to increased Z0-1 and occluding mRNA in the jejunum section 
which are major markers of tight junction integrity [106]. Furthermore, systemic 
and hepatic inflammation was shown to be improved given that the plasma 
cytokine and chemokine concentration decreased in obese mice that was fed 
prebiotic [106]. The reduced oxidative stress markers such as PAI-1, CD68, 
NADPHoX and iNOS mRNA concentrations led to decreased TLR4 and TNFα 
mRNA concentration [106]. Also, these markers were greatly reduced as the 
number in bifidobacteria spp. increased. Furthermore, as the gut microbiota 
changed in the prebiotic fed mice, the gastrointestinal peptide, GLP-1, 
significantly increased and led to reduced appetite [106].  
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Furthermore, the study by Cani et al., (2008) also showed that high –fat 
diet greatly changed the gut microbiota content in obese mice [74]. There was a 
reduction of Bifidobacterium spp., Lactobacillus spp., and Bacteroides- Prevotella 
spp. High –fat diet also reduced intestinal permeability by reducing the 
expression of epithelial tight junctions such as ZO-1 and occludin [74]. The 
reduced intestinal permeability was the mechanism through which high –fat diet 
induced metabolic endotoxaemia by increased intestinal LPS permeability 
followed by increased mRNA concentration of PAI-1, IL1 and TNFα, which are 
oxidative stress marker and pro-inflammatory cytokines [74]. Furthermore, 
during the glucose challenge, it showed that high –fat feeding induced glucose 
intolerance. This is evident in the study as high-fat fed obese mice had higher 
blood glucose concentration compared to the control obese mice [74]. Also glucose-
induced insulin secretion, insulin resistance index, body weight gain, total energy 
intake, and visceral and subcutaneous adipose weight were all higher in high- fat 
diet fed obese mice [74]. Interestingly, high- fat fed obese mice that received 
antibiotic treatment had a complete reversal of the above mentioned bacterial 
composition and /or metabolic activity [74]. The reason is that antibiotic 
treatment reduced the number and effect of pathogenic bacteria and the number 
of Gram-positive bacteria increased and improving all adverse conditions noticed 
[74]. These results led to a conclusion that gut microbiota, intestinal permeability 
and endotoxemia by increased LPS levels during high- fat diet leads to the onset 
of metabolic disorders such as obesity and diabetes [74]. Another aim of the study 
was to show that gut microbiota does contribute to metabolic endotoxaemia in the 
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absence of high- fat diet. The obese mice were not fed with high- fat diet yet they 
had higher inflammatory tone and plasma LPS concentrations. This could be as a 
result of the ability of the gut microbiota in obese phenotype to harvest energy 
from the diet and general energy storage [74].  
This was further illustrated by Bäckhed et al. (2004) in their study of a 
mice model of obesity and showed that in 14 days adult germ –free C57BL/6 mice 
conventionalized with a normal microbiota harvested from the cecum of 
conventionally raised animals, produced a 60% increase in body fat and insulin 
resistance. This happened despite reduced food intake [107] . 
In humans with obesity and diabetes, Creely et al., (2006) showed that in 
T2D there is a decrease in the phylum Firmicutes, class Clostridia, and 
Bifidobacterium genus. The ratio Bacteroidetes to Firmicutes and 
Betaproteobacteria positively correlated with plasma glucose concentration (but 
not BMI). T2D patients also had higher circulating serum LPS compared to the 
lean healthy subjects. This was expected given that the T2D patient had higher 
levels of phylum Bacteroidetes and Proteobacteria compared to the healthy 
controls. Furthermore, in obese and T2D patients, in isolated abdominal 
subcutaneous adipocytes, LPS activated the innate immune pathway and 
stimulated the secretion of pro-inflammatory cytokines (16). Likewise, in 
adipocytes increased expression of innate immune system pathway factors was 
observed. This clearly suggests that LPS causes inflammation in T2D and 
diabetic patients appear to be at greater risk of developing inflammation through 
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endotoxins (16). Similarly, an association between insulin and endotoxin was 
observed as hyperinsulinemic / insulin-resistant in obese phenotype. However, 
this association is not clearly understood. These results presented in this study 
suggested a strong link for gut microbiota in the pathogenesis of obesity-related 
T2D and the innate immune response. 
Similarly, in humans with T2D, Larsen et al., (2010) showed that there 
was a significant reduction in the level of the phylum Firmicutes and Clostridia 
and increase in the level of phylum Bacteroidetes and Proteobacteria. The level of 
the latter negatively correlated with plasma glucose concentration. Also, there 
was a positive correlation between the ratio of Bacteroidetes to Firmicutes with 
glucose intolerance but not Body mass index (BMI). This is an indication that the 
dysbiosis in T2D and obesity differs [108]. 
 
1.8. Metformin – inflammation and gut microbiota 
Metformin is known for its ability to lower glucose production in the liver, 
but much more it has been shown to have anti-inflammatory effect as well as 
altering the gut microbiota [6, 109, 110]. In mice models of T2D and obesity, it 
has been shown that increased intestinal LPS permeability led to increased 
mRNA concentration of IL1, IL6 and TNFα which are pro-inflammatory cytokines 
[72, 74].The nuclear transcription factor-kappa B (NF-kB) plays a central role in 
mediating cytokines , which when activated transcriptionally activates multiple 
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pro-inflammatory cytokines including IL1 , IL-6, IL-8, and TNFα [6]. In a cell 
culture model of atherosclerosis, the anti-inflammatory effect of metformin was 
investigated in human vascular smooth muscle cells (SMC), macrophages (Møs), 
and endothelial cells (ECs) [6]. Since, cytokines such as IL-8 and IL-6 may likely 
contribute to monocyte recruitment and adhesion to ECs in atherosclerosis, as 
well as drives the acute phase response respectively, the study aimed at 
demonstrating that metformin inhibits IL-1 –induced IL-6 and IL-8 expression by 
impaired NF-kB nuclear activation [6]. Metformin inhibited IL-1 induced 
cytokine production. This was evident in study as IL-6 and IL-8 expression from 
SMCs, ECs, and Møs was reduced in a concentration dependent manner. IL-6 and 
IL-8 production were lower at low concentrations. Furthermore, IL- 1 stimulated 
SMCs showed activation of all three mitogen-activated protein (MAP) kinases 
(p38, JNK, and Erk) and Akt which are all part the inflammatory signalling 
pathway. The p38 kinase regulates various transcription factors, including NF-
kB. . Metformin treatment inhibited IL-1–induced p38, JNK, and Erk 
phosphorylation but not Akt in SMCs. These results were obtained using 
metformin at a concentration that exceeded its therapeutic plasma concentration 
(max 20µmol/L). In ECs, high glucose leads to activation of PI3K and Akt, as well 
as NF-kB activation. ECs stimulated with high glucose induced phosphorylation 
of Akt. To show that metformin inhibitory effect occurs at therapeutic plasma 
concentrations (20µmol/L), ECs pre-treated with metformin and then exposed to 
high glucose, showed decreased Akt phosphorylation. The findings of this study 
support the author’s conclusion that metformin attenuate inflammation in 
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atherosclerosis, which may explain why it reduces macrovascular complications 
of diabetes aside its glycaemic effect [6]. 
Secondly, Napolitano et al. (2014) believed metformin could alter bile acid 
circulation and gut microbiota which could enhance entero-endocrine hormone 
secretion. To validate this, 14 T2D subjects were studied at for time points; i) 
patients on metformin sampled at baseline (visit 1) , ii)7 days after metformin 
was stopped (visit 2), iii)when fasting blood glucose raised by 25% after 
metformin was stopped(visit 3) and iv) when fasting blood glucose reached 
baseline after metformin intake was resumed (visit 4). This study established 
that total bile acids in serum and secondary bile acid (lithocholic and deoxycholic 
acids) in faeces greatly increase upon metformin withdrawal. This indicates that 
metformin indirectly inhibits the reabsorption of bile acid in the gut through the 
sodium –dependent intestinal bile acid transporter. Also, the activity and amount 
of GLP-1 was reduced which suggests that metformin may act on the 
metabolizing enzyme, DPP-IV which is a GLP-1 and PYY inhibitor. Furthermore, 
this study established a change in the gut microbiota in T2D patients when on- or 
off-metformin. The microbiota analysis showed that the T2D Patient’s on-
metformin had significantly high levels of the phylum-genus; Firmicutes- SMB53, 
Actinobacteria-Adlercreutzia and low level Firmicutes-Eubacterium. However, 
Firmicutes-Eubacterium was significantly higher in patients’ off-metformin. This 
significant difference was not observed for the interaction of metformin treatment 
and bacterial species after multiple factor correction. Also taxa level varied 
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between subjects as evident on the PCoA plots which had no distinct sample 
clustering. Although this study had interesting findings, the limitation was the 
small number of subjects studied which made it difficult to determine subgroup 
differences and if these groups increased or reduced the efficacy or side effect of 
metformin [109].  
Thirdly, the role of metformin in changing the composition of the gut 
microbiota in diet-induced obese and diabetic C57BL/6 mice was investigated 
[111]. The significant reductions in the proportions of Akkermansia and Alistipes 
and the increases in the proportions of Anaerotruncus, Lactococcus, 
Parabacteroides, Odoribacter, Lawsonia, Blautia and Lactonifactor, seen in high- 
fat diet fed mice, were reversed by metformin to a similar genera proportion in 
the normal chow diet mice. Akkermansia are mucin –degrading bacteria that 
have a protective effect on the intestinal tract by increasing the number of goblet 
cells [111]. The level of Akkermansia in high- fat diet fed mice after treatment 
with metformin greatly increased the number of mucin-producing goblet cells. 
Also, the role of the gut microbiota in aiding the effectiveness of metformin was 
shown in high-fat diet mice treated with Akkermansia. The mice had improved 
glucose intolerance and increased goblet cell number. Hence it can be that 
metformin improves glucose intolerance by increasing the level of Akkermansia, 
which increases the number of goblet cells [111]. 
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1.9. Methods used to study human gut microbiota 
Most studies used culture independent methods to characterise the gut 
microbiota. This is because most bacteria in the gut are not easily or cannot be 
cultured in the laboratory[53]. Culture independent methods are high through 
put methods and do not require the growth of bacteria which makes it less 
susceptible to contamination [53, 112]. The methods include polymerase chain 
reaction (PCR) based DNA profiling, quantitative PCR (QPCR), fluorescent in 
situ hybridization (FISH), flow cytometry, DNA microarray and DNA sequencing. 
Of these methods, DNA sequencing is the most commonly used method. The 
molecular marker used for genetic diversity of bacteria is the 16s ribosomal RNA 
(16s rRNA) [113].  
Recent technologies with high throughput systematic sequencing are 
referred to as Next generation sequencing (NGS). NGS systems include Sanger 
sequencing, Illumina Genome Analyzer II system, Roche 454, GS FLX Genome 
Analyzer (Pyrosequencing), Applied Biosystems's solid system, and Helicos 
HeliScope [112]. These high throughput sequencing techniques have different 
features and principles but their common advantages include higher throughput 
efficiency, increased sensitivity, and sequencing of multiple samples at once [112, 
114]. However, a huge amount of sequence data is generated by the high 
throughput sequencing techniques and this requires extensive bioinformatics 
analysis. Also, the high throughput sequencing techniques has higher error rate 
due to the shorter sequence reads (<500 bp) produced [112].  
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The NGS technologies have been used mainly for metatranscriptomics and 
metagenomics studies. Metatranscriptomics and metagenomics rely on RNA and 
DNA sequencing method respectively [112]. Although both methods can be used 
to determine the function of the gut microbiota, metatranscriptomics provides 
information on alterations in gene expression in relations to changes in the host 
and diet impact. Metagenomics gives insight about the composition by giving 
sequence information from the collective genomes of the microbiota in a single 
experiment [112, 115, 116]. The metagenomic technique has advantages such as 
its high throughput and ability to identify new functional genes. However, given 
that collective genome of the microbiota is sequenced, the DNA from dead cells 
cannot be distinguished from the DNA of live cells [117]. This challenge does not 
apply to metatranscriptomics because it’s an RNA based techniques which only 
expressed genes have been transcribed to RNA and then translated to protein 
[112]. In both methods, faecal samples are used because of the easy collection 
[112]. 
 
1.10. Aims of the research project 
The gut microbiota can be a potential therapeutic target for metabolic 
diseases such as T2D. Since most studies have been conducted in animal models, 
the need for more human studies becomes imperative to further understand the 
role disease play in shaping the gut microbiota. Many studies have successfully 
differentiated the gut microbiota in both healthy individuals and T2D. However, 
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the role of the participant’s genetics, diet, and geographical location and research 
methods used in the various studies can lead to varying outcome. The need for 
more research on this topic to contribute to the growing knowledge of the study of 
the gut microbiota in human T2D. Furthermore, there is a need to use faeces 
experimentally as faecal water, which may be a potential research approach to 
investigate the activity of bacteria in human in-vitro. Thus the overall aim of this 
study was to investigate the impact of T2D on the gut microbiota, an important 
‘organ’ that had the potential to influence disease progression and the activity of 
faecal water from T2D patients on colon cells as a measure of disease state by 
correlating the results with markers of T2D.  
This thesis aimed to: 
I. Elucidate the differences in the gut microbiota of type 2 diabetic patients 
and age, sex, and BMI matched healthy controls using next generation 
sequencing. 
II. Investigate the benefit of GOS on gut microbiota composition after 
prebiotic intervention in a double-blinded human studies involving T2D 
patients and matched healthy controls.  
III. Investigate the impact of T2D and healthy controls FW samples prepared 
in-vitro, to mimic a complex mixture of both host and bacteria compounds 
using a Caco-2 monolayer cell culture model of intestinal epithelium and 
linked it to T2D patient’s metabolic markers measured in the blood. 
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IV. Investigate the protective effect of GOS against the cytotoxic effect of FW 
extracted from the faeces of T2D patients and healthy controls on Caco-2 
cells using cell viability assays as a measure of cytotoxicity.  
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2. Materials and Methods 
2.1 Faecal bacteria DNA extraction 
The DNA was extracted, according to the manufacturer’s protocol, using 
the Cambio PowerFeacalTM DNA isolation Kit (Cambio, UK), with slight 
modifications. Briefly, 0.25g of the faecal sample was added to a 2ml Dry Garnet 
Bead Tube. Samples were lysed by both chemical and mechanical disruption. The 
sample was chemically disrupted by addition of the provided bead solution and 
subsequent incubation at 65oC for 10 minutes. Modification to the protocol (in 
place of vortex for 10 minutes) included mechanical disruption of the sample 
using beads grinding at 5.0 speed for 30 seconds using a FastPrep FP120 
(Thermo Savant). PCR inhibitors were removed by binding the DNA on a silica 
spin filter membrane; samples were washed to remove contaminants and pure 
genomic DNA eluted in TE buffer. The DNA concentration and quality was 
determined using a Nanodrop 2000 (Thermo Scientific) and Qubit 2.0 fluorometer 
(Invitrogen). 
 
2.1.1 Determination of DNA concentration using Qubit® 2.0 Molecular probe 
fluorometer Invitrogen (Life Technologies)  
 
 DNA sample concentrations were measured using a Qubit and samples of 
50ng/µl were sent to Animal and Plant Health Agency (APHA) for next 
generation sequencing as described in Section 3.4 .For the standards, two assay 
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tubes were set up and one for each of the samples. The Qubit working solution 
was prepared by diluting the Qubit reagent 1:200 with the Qubit buffer. 200μL of 
working solution was prepared for each standard and sample (190μL of working 
solution was added to 10μL of the standard while 198uL of working solution was 
added to 2μL of each sample). The tubes were vortexed for 3 seconds and 
incubated for 20 minutes at ambient temperature. Each tube was then inserted 
into the Qubit fluorometer and the DNA concentration was measured. 
 
2.2 DNA polymerase chain reaction (PCR) 
PCR inhibitors generally exert their effects through direct interaction with 
DNA or interference with thermosTable DNA polymerases. Direct binding of 
agents to single stranded or double-stranded DNA can prevent amplification and 
facilitate co-purification of inhibitor and DNA (Promega). The absence of PCR 
inhibitors in the extracted DNA was confirmed by amplification of bacterial and 
archaea 16S rRNA V4-V5 region as follows; A 50 µl reaction contained 5x Go Taq 
G2 buffer (Promega), 10 mM of each Deoxynucleotide Triphospahe (dNTPs) 
(Promega), 10 pmol each of the forward (U515F- 5′-GTGYCAGCMGCCGCGGTA 
and reverse primer (U927R- 5′-CCCGYCAATTCMTTTRAGT) [57], 5 u of GoTaq 
G2 DNA polymerase (Promega), and 2 µl of the template DNA. The volume was 
then adjusted with nuclease free water to a total volume of 50µl. Amplification 
was performed using a thermal cycler (Applied Biosystems, UK), under the 
following cycling conditions: 94°C for 3 minutes; 30 cycles of 94°C for 30 seconds, 
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55°C for 45 seconds, 72°C for 1 minute; followed by a final extension at 72°C for 8 
minutes. 
 
2.2.1 Agarose gel electrophoresis  
Agarose gel electrophoresis uses an electric field to separate DNA 
fragments according to their sizes. Agarose (Fisher Scientific, UK) was weighed 
and dissolved in a solution of 1 X Tris/Boric EDTA (TBE) by heating, resulting in 
a final concentration of 1% (w/v) and then 5 µl of RedsafeTM (Ecogen), a nucleic 
acid stain, was added to the 1% agarose gel. 
For detection of the PCR amplicon, 5 µl of the reaction products were 
mixed with loading buffer (at a ratio of 5:1) and loaded on the gel. A 
corresponding 1 Kb DNA ladder (Promega), were also loaded each time to 
estimate the size of the desired bands. The gel was run at 100V for 45 minutes-1 
hours to allow separation of bands in 1 X TBE. DNA bands were visualised with a 
Gel Documentation system (GeneFlash Syngene, Bio Imaging). 
 
2.3 Tissue Culture Methods  
The human adenocarcinoma cell line (Caco-2) was used. The cells were 
kindly provided by Dr. Jenny Ritchie at passage number 12. Cells were used for 
experiments between passages 14-25. Cells were cultured in DMEM (with L-
glutamate) supplemented with 10% Foetal Bovine Serum, 1% Non-essential 
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amino acids, 1% Penicillin-Streptomycin and maintained at 37oC in a humidified 
environment supplied with 5% CO2. Depending on the type of experiment being 
conducted, cells were grown in T75 flasks, T25 flasks, 12-well plates (transwells) 
and 96-well plates. The culture media used is also described in Table 2.2. Passage 
of confluent adherent cells was done by removing the existing medium, washed 
with phosphate buffered saline (PBS) and covered in 0.25% Trypsin-EDTA for 
five minutes to allow cells to detach. Trypsin action was stopped by adding 
culture medium and the cells were pelleted by centrifugation (4 minutes, x 2500 
rpm) in a swinging bucket rotor for the Hereaus Megafuge 16R (Thermofisher 
Scientific). Pellets were re-suspended in fresh media, counted and plated at the 
required number and stored in the incubator at 37oC. For cryopreservation, 
aliquots of the culture cells in 10% DMSO were stored in liquid nitrogen (-196oC) 
for long-term storage. Cells were counted prior to seeding the culture plates as 
described below. 
 
2.3.1 Cell Enumeration 
Cell suspensions were diluted in 0.4% Trypan blue solution and cell 
medium at a ratio of 1:1:5 and 10μL of this mixture was transferred to each 
chamber of a haemocytometer (Neubauer chamber). The cells were counted under 
an inverted microscope. Non-viable cells take up Trypan blue dye, hence, it is 
possible to distinguish between non-viable and viable cells. Each square of the 
heamocytometer with 13mm cover slip in place represents a total volume of 0.1 
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mm3. 1 cm3 is equivalent to 1 mL, so that cell concentration per mL was 
determined by multiplying the average number of cells per square by the dilution 
factor and also by the area covered by the grid lines (104) using the formula 
below:  
Cells per mL = the average count per square x dilution factor x 104 (a 
constant).  
For example: if the average count per square is 50 cells x 5 x 104 = 2.5 x 
106 cells/mL. 
 
2.4 Transwell tissue culture assay 
Polyester transwell (PET) Clear inserts have microscopically transparent 
polyester membranes that are tissue culture treated for optimal cell attachment 
and growth. Transwell-Clear inserts provide better cell visibility under phase 
contrast microscopy. It also allows for assessment of cell viability and monolayer 
formation (Corning Incorporated, Life Sciences). Caco-2 cells were grown on 
transwell filter inserts (0.4 μm pore size, polyester, 12- mm inside diameter; 
Corning Incorporated, Corning, NY) at a density of 1 x 105 cells per well. The 
culture medium was changed every 2 days for 15 days until a differentiated Caco 
-2 monolayer was achieved. The monolayer integrity was evaluated by measuring 
the transepithelial resistance (TER) using an EVOM2 Epithelial Voltohmmeter 
and wells with TER reading above 900 ohms were used in the experiment. Cell 
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medium was gently aspirated from the apical and basolateral compartments. 
500µl of FW (2.5% w/v) for sample well or cell medium for control well were added 
to the apical side of the inserts of the transwells and the basolateral side was 
bathed in 1.5ml cell medium. The resistance of a blank (culture insert without 
cells) was measured to correct for background resistance. The plates were 
incubated at 37oC with 5% CO2.  
 
2.5 Transepithelial electric resistance (TER) measurements 
TER is used as a measure of cell monolayer integrity for confluent cells 
grown on transwells. The higher electric resistance indicates the formation of 
good cell monolayer. TER measurements for all samples were performed within 5 
min after taking the culture plates out of the incubator to eliminate the influence 
of temperature. Prior to taking the measurements, the electrodes were sterilized 
using 70% ethanol and equilibrated in pre-warmed cell medium. The electrode 
was then inserted into the EVOM2 Epithelial Voltohmmeter (World Precision 
Instruments). The change in TER was measured in ohms before the experiment 
(Initial), at the start of experiment, at 24 and 48 hours. The TER of the sample 
well was obtained by subtracting the blank value from the total resistance of the 
sample. Uninfected well TER readings were adjusted to 100% and the values of 
sample wells expressed as a percentage of the uninfected well. 
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2.6 Human faecal water sample preparation 
Faecal water was extracted by adding 40ml PBS to 1g of faeces (2.5% w/v) 
and homogenised using a Masticator® Homogenizer Blender (MG Scientific) for 
5mins. The homogenate was transferred to a tube and centrifuged at 39,800 g in 
an Avanti J-26S XP centrifuge (Beckman Coulter) for 2 hours at 4oC. 35ml of the 
supernatant was transferred to a clean tube and centrifuged at 3725g in an 
Allegra X-15R centrifuge (Beckman Coulter) for an additional 20 minutes at 4oC 
to remove remaining debris present in the supernatant. The clear supernatant 
was then filtered using a 0.22µm filter and aliquots of the supernatants (faecal 
water) were placed into 2ml Eppendorf tubes and stored at −80 °C prior to 
analysis. 
 
2.7 Determination of faecal cytokines using Human Cytokine array  
2.7.1 Faecal Protein Extraction 
For each sample, 0.1 g of faeces was weighed into a sterile eppendorf tube, 
and 0.4 mL RIPA lysis buffer was added. The samples were then vortexed for 1 
min, followed by a 5-min incubation in an ice bath until no visible faeces granules 
remained. The samples were then centrifuged at 13,000 rpm for 5 minutes at 4oC 
to remove cell debris. The supernatant fraction was collected into a fresh tube 
and placed on ice for 1 hour, centrifuged for 30 min at 13,000 rpm at 4 °C. The 
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supernatant fraction was collected again and stored at -80 °C until further 
analysis. 
 
2.7.2 Determination of Protein Concentration 
Thermo Scientific Pierce BCA Protein Assay Kit (Catalogue No. 23225) 
was used to determine protein concentration according to the manufacturer’s 
instruction. Briefly, bovine serum albumin (BSA) standards of known 
concentrations were made up in distilled water. The working reagent (WR) was 
prepared by mixing 50 parts BCA Reagent A with 1 part BCA Reagent B (50:1, 
Reagent A: B). For standards and unknown samples, 10μL of each was added to a 
sterile 96-well microplate in triplicate and 200μL volume of the WR was added to 
each well and mixed thoroughly on a plate shaker for 30 seconds at ambient 
temperature. The plates were then incubated at 37oC for 30 minutes and the 
absorbance was measured at 540nm using a spectrophotometer (Omega 
Fluorostar, Switzerland). 
 
2.7.3 Cytokine Array 
RayBio® C-Series Human Cytokine Antibody Array 1 Kit (RayBiotech- 
AAH-CYT-1-8) detects 23 Human Cytokines and suitable for all liquid sample 
types (Figure 2.1). It is a membrane, sandwich based, semi- quantitative method 
for detection of protein expression of cytokines in biological fluids. This assay was 
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used to identify the cytokines present in the stool samples of T2D patients and 
was performed according to the manufacturer’s protocol. Briefly, membranes are 
blocked with blocking buffer for 30minutes, incubated with faecal protein (50µg) 
overnight at 4OC, membranes washed and then incubated with Biotinylated 
Detection Antibody Cocktail. Also, membranes were washed, incubated with 
HRP-Conjugated Streptavidin, washed again and then incubated with detection 
Buffers. All incubations ware performed for 2 hours at ambient temperature, 
unless otherwise stated. Images of the membranes were taken with 
chemiluminescent imaging system, and Image was used to quantify each blot on 
the membrane and analysed using the Software tool for RayBio Human Cytokine 
Antibody Array 1(S02-AAH-CYT-1). 
 
Figure 2-1: RayBio® C-Series Human Cytokine Antibody Array 1 Kit 
List of 23 human cytokines detected by the array using the human faecal protein from type 2 
diabetes patients. 
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2.8 Cell viability assay to measure faecal water cytotoxicity 
To determine the cytotoxicity of FW, cells were seeded at 2x104 cells/100µl 
in a 96well plate for 48hours and the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega), a colorimetric method for determining the number 
of viable cells was used according to the manufacturer’s instructions. The 
CellTiter 96® AQueous One Solution is MTS and an electron coupling reagent 
(phenazine ethosulfate; PES. The 3-(4,5-dimethyl-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS assay 
is based on the cellular reduction of MTS by the mitochondrial dehydrogenase of 
viable cells, to a formazan product that is soluble in tissue culture medium, 
because combined with PES , MTS forms a stable solution.  
After 2 hours incubation with FW in triplicate, the FW was removed from 
the cells, replaced with 100µl of sterile medium, then 20μL of MTS solution was 
added into each of the 96-well plates, and incubated for 4 hours at 37OC. 
Following incubation, optical density was measured using a spectrophotometer 
(Omega Fluorostar, Switzerland) at 540nm. Cells with media were used as 
positive controls, while cells lysed with 1% Triton X-100 were used as negative 
control. The percentage viability of each sample was derived by dividing the 
sample OD by the OD of the positive control, hence the positive control is used as 
100% cell viability. 
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2.9 Cell viability assay to investigate the effect of GOS against FW cytotoxicity 
2.9.1 Galactooligosaccharide (Bimuno) Preparation 
Bimuno is a daily food supplement containing unique patented GOS 
developed by scientist working at the University of Reading [78] . Bimuno 
ingredients as detailed on product includes GOS, lactose (from milk), glucose 
syrup, thickener (gum Arabic), galactose, and acidity regulator (trisodium 
citrate). Galactooligosaccharide stock solutions of 20% w/v were prepared by 
weighing 5.5g of commercially available GOS powder (Bimuno) and 25ml of cell 
culture media. From the stock, a 5%, 10% and 15% v/v solution was then 
prepared by diluting in cell culture media. The solutions were thoroughly mixed 
by inverting the tube several times until solutions had no visible particulate 
matter. 
 
2.9.2 3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt (MTS)Assay  
Caco-2 cells were seeded at 2x104 cells/100µl in a 96well plate and 
incubated for 48 hours. At 48 hours, cells were pre-treated in duplicate with 
either 5%, 10% or 15% v/v (100µl) GOS solution and incubated for 2 or 12hours. 
At the end of the pre-treatment, in order to assess GOS effect on cell viability, 
MTS assays were performed on the cells. For investigating GOS effect against 
FW cytotoxicity, GOS was either removed or left on cells and 100µl of each FW 
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was added to the wells and incubated for 2hours. After incubation, FW was 
removed from the cells and MTS assay performed. MTS assay was performed as 
described in section above. Cells with culture medium were used as positive 
controls, while cells killed with 1% Triton X-100 were used as negative control. 
OD of the MTS assay was measured and analysed as described above in section 
2.8. 
 
2.10 Statistical analysis 
Experimental data were analysed as stated in the method section of the 
individual chapters of this thesis. Dr Huihai Wu (Department of Bioinformatics, 
University of Surrey) and Peter Williams (Department of Mathematics, 
University of Surrey) were consulted to analyse the data in Chapter 3 and 4 
respectively. Otherwise, data were analysed using the One-way ANOVA, T-test 
and linear regression analysis using the statistical package of GraphPad7 Prism 
software (Graphpad, California,USA) 
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CHAPTER 3 
 
 
UNDERSTANDING THE GUT 
MICROBIOTA IN HUMAN TYPE 2 
DIABETES 
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3. Understanding the Gut Microbiota in Human Type 2 Diabetes 
3.1. Introduction 
T2D is considered a low grade inflammatory disease, but the exact 
mechanism through which this occurs is unknown. A number of animal models 
have been used to investigate the gut microbiota in T2D, and results showed an 
increased bacteria population belonging to the phyla Bacteroides. LPS is an 
endotoxin that on entering the circulation of the host, can lead to endotoxaemia 
and inflammation [73, 108].  
It has been proposed that high-fat feeding is a major trigger leading to 
bacterial population shifts in the human gut, in addition to chylomicron 
formation as a source of blood LPS per se [72]. More recently human studies have 
confirmed these early bacterial composition changes in T2D patients, however, as 
the aetiology of human and animal diabetes is not always comparable, many of 
the features of this microbial alteration remain to be understood. When analysing 
the literature, bacterial populations have been shown to be affected by the host 
genetics, age, gender, ethnicity and geographical location. Additionally, sample 
storage, DNA extraction and analysis methods such as qPCR, FISH, and next 
generation sequencing (NGS) can contribute to the considerable variation found 
between individual studies [114, 115]. These diverse factors make it necessary for 
more human clinical studies to be performed, possibly to broaden the scope and 
further understand the role these microbial changes may have for host 
metabolism.  
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3.2. Hypothesis 
This chapter aimed to test the hypothesis that the gut microbiota in 
patients with T2D would be significantly altered in age, gender and BMI matched 
healthy controls and that the dietary supplementation with a pre-biotic 
carbohydrate with documented effects in healthy participants (galacto-
oligosaccharide) would normalise the gut microbial population back to the non-
diabetic “state” when used in a group of T2D patients. 
The aims and objectives of this chapter were to: 
1. Extract faecal DNA from both healthy controls and T2D subjects and 
assess the integrity of DNA for application in NGS using nanodrop and 
Qubit 
2. Investigate the difference in gut microbiota composition between healthy 
controls and T2D patients using the healthy control and T2D extracted 
DNA sequenced data and differential statistical analysis. 
3. Investigate the effect of GOS treatment on the gut microbiota in T2D using 
the T2D faecal extracted DNA sequenced data and differential statistical 
analysis. 
4. Investigate the potential effect of the oral diabetic agent metformin on the 
gut microbiota using the T2D faecal extracted DNA sequenced data and 
differential statistical analysis. 
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5. Investigate the gut microbiota composition in healthy controls split by BMI 
using the healthy controls faecal extracted DNA sequenced data and 
differential statistical analysis. 
 
3.3. Study Design 
 Study Plan 3.3.1.
This study was undertaken (funded by the European Funds for the Study 
of Diabetes) in the format shown below (Fig. 2.1). This was performed using a 
mixed study design: 
- Cross-Sectional Study 
- Randomized Controlled Parallel (Parallel RCT) Study 
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-  
 
Figure 3-1: Diagram showing the study plan with the two 
study methods used.  
A total of 60 human subjects were recruited comprising of 
T2D patients (30) and healthy controls (30). The T2D group 
was randomised into two groups, prebiotic or placebo 
treatment groups. Baseline measurements were taken for all 
subjects, and treatment with prebiotic or placebo (n=15 per 
group) lasted for a period of 12 weeks. The control group 
consisted of both obese and lean individuals (n=15 per 
group).  
 Inclusion and exclusion criteria 3.3.2.
Eligible subjects were between the ages of 40 and 65 years and 
with/without T2D. Reasons for exclusion from study were: 
- Current or previous use of antibiotics in the previous three months 
- Concurrent use of Non-steroidal Anti-inflammatory drugs (NSAID’s) 
- A positive history of inflammatory bowel disease (IBD) 
- Impaired renal function (Estimated Glomerular Filtration Rate, eGFR < 
60). 
Recruitment of Patients with 
T2DM and matched control and 
obese subjects
Patients with T2DM enter 
Parallel RCT
Obese and lean
controls 
enter cross-sectional study
n = 15
Baseline Measurements
n = 15
Baseline Measurements
n = 15 per group
No treatment
n = 15
12 weeks placebo treatment
n = 15
12 weeks prebiotic treatment
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 Treatment plan- 12 weeks prebiotic/placebo 3.3.3.
In the parallel RCT study consisting of 30 T2D subjects, prebiotic 
(Galactooligosaccharide (GOS)) or placebo (Maltodextrin) was provided in 
individual sachets (5.5g powder) enough to last for a period of 12 weeks. GOS 
used in this study is the commercially available Bi2muno ® (B-GOS, 52% GOS 
content) supplied by Clasado Ltd, (Milton Keynes, United Kingdom). The major 
importance of B-GOS is the use of a specific probiotic (Bifidobacterium bifidum 
NCIMB 41171). It is produced from the activity of galactosidase enzymes isolated 
from this strain, hence it has increased bifidogenic property [78, 83]. 
Patients were instructed to take one sachet daily (GOS or Maltodextrin) 
and to stop the consumption of yoghurt for the period of treatment. The group 
taking GOS or Maltodextrin were known as L and T, respectively. However, the 
content of the sachet taken in L and T groups was unknown during the study, 
making it a double-blind study.  
 
 Faecal Sample Collection 3.3.4.
Subjects were provided with sterile collection bottles and bed pans to 
ensure collection of samples were done in sterile holders. Subjects were 
instructed to keep samples cold after collection and for < 2 hours before their 
study visits. The healthy controls had no treatment and provided one sample 
while the T2D patients in the L and T groups provided two samples, before and 
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after treatment for 12 weeks. The samples provided by the T2D patients were 
labelled as pre and post samples. Samples consisted of 90 samples from T2D 
(n=30) and matched (n=30) adult males (age 45-60 years old). Faecal samples 
were collected and stored initially at -20oC and at -80oC for long term storage, 
until further processing. 
 
3.4. Next generation sequencing (NGS)  
Genomic DNA samples were extracted and sent to the Animal and Plant 
Health Agency (APHA) for next generation sequencing. Only DNA samples with 
concentration ≥ 50ng/µl were eligible, hence 27/30 control subjects and 52/60 T2D 
patients DNA samples were included in the NGS. The sequences were processed 
in Qiime using the AmpliconNoise pipeline that utilises flowgram information of 
the sequences to correct for errors. The samples were demultiplexed by exact 
matching of both barcode and primer and the sequences filtered and trimmed 
based on identification of low quality signals. The filtered flowgrams were 
clustered to remove platform-specific errors and converted into sequences using 
the PyroNoise algorithm. The sequences had barcodes and degenerate primers 
removed prior to trimming at 500 base pairs (bp). They were then further 
clustered by SeqNoise to remove PCR single base errors. In the final step, the 
Perseus algorithm was used to identify chimeras. 
The de-noised sequences were classified using the standalone RDP classifier. 
From this, taxa frequencies at five different levels: Phylum, Class, Order, Family 
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and Genus were calculated. Additionally, a non-supervised approach was used, 
operational taxonomic units (OTUs) were generated at 3% divergence following 
pair-wise global sequence alignment and hierarchical clustering with an average 
linkage algorithm. To improve resolution at the OTU level, sequences were also 
compared with databases at the NCBI website 
(http://blast.ncbi.nlm.nih.gov/blast.cgi). Further statistical analyses were 
performed in R using the Tables and data generated as above, in addition to the 
meta-data associated with the study. For community analyses (including alpha 
and beta diversity analyses) we used the vegan (http://cran.r-
project.org/web/packages/vegan/) package. To calculate Unifrac distances (that 
account for phylogenetic closeness), we used the phyloseq, ape, and phangorn 
packages. To determine significant differences in bacterial abundances between 
the groups, we used DESeqDataSetFromMatrix function from DESeq package 
with a significance value cut-off of 0.05. This function allows negative binomial 
GLM fitting (as abundance data from metagenomic sequencing is overdispersed) 
and Wald statistics for abundance data and identifies species with log-fold 
changes between different conditions [118]. 
 
3.5. Statistical analysis 
The statistical analysis was kindly performed by Dr Huihai Wu 
(Experimental officer in Bioinformatics, University of Surrey). Baseline values 
were compared between the healthy controls and T2D group using an unpaired t 
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test or Mann-Whitney test , while treatment effects were assessed by comparing 
the differences in changes from baseline within the T2D group using a paired t 
test or Wilcoxon’s matched pairs signed –rank test.  
The cross-sectional study data analysis was performed for T2D patients 
(pre samples) versus the healthy controls. Furthermore, the parallel RCT study 
data analysis was done for treatment (L) versus placebo (T) groups of both the pre 
and post samples of the T2D group. Although 27/30 control subjects DNA samples 
were sent for sequencing, only 26 were included in the statistical analysis as one 
subject was taking antibiotic during the study. In the T2D group, for it to be 
included in the analysis it had to be a complete pair, pre and post samples of an 
individual subject. Only 23 subjects had complete pairs with 11 and 12 in the 
treatment and placebo groups respectively.  
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3.6. Results. 
 Amplification of extracted faecal DNA  3.6.1.
In this study, although both the Nanodrop and Qubit fluorometer were 
used to determine the quality and quantity of the DNA, the results of the Qubit 
fluorometer was relied on, which was used to determine those samples to be 
included in the sequencing. PCR was used to amplify the DNA and PCR products 
with bands on a gel electrophoresis of expected product size were considered 
suitable for sequencing. PCR amplification of the V4-V5 region of 16s ribosomal 
RNA gene for both bacteria and archaea was performed for 79 DNA samples 
(≥50ng/µl). As expected, bands for the amplification of the V4-V5 region of 16s 
rRNA genes were successful for the 79 PCR amplified products and negative 
control, containing no DNA had no band (see Figure 3.1). The DNA samples (not 
PCR product) were sent to APHA for 16s rRNA next generation sequencing. 
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Figure 3-2: 1% agarose gel PCR amplification fragments of the 16S V4-V5 region 
amplicon  
1kb ladder (Promega); Lane 1- 1kb DNA ladder; lanes 2-9 and 12-14 are PCR products 
for the DNA extracted from the subjects both T2D and healthy controls while lane 10 is 
a negative control which has no band. This shows that the extracted DNA were free of 
PCR inhibitors and suitable to be sent for next generation sequencing. The amplicon 
size was approximately 400bp. This is a representative gel image of the PCR amplicons 
from all healthy controls and T2D subjects, which were sent to APHA for next 
generation sequencing. 
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 16s rRNA Sequences constituted of mostly bacteria products 3.6.2.
The primers used were optimised to identify the V4-V5 of 16s rRNA of both 
bacteria and archaea and the result showed that approximately 99.99% of 
sequence from the sequencer are bacteria products. This implies that the genomic 
DNA extracted from faecal samples was mostly that of bacteria (see Figure 3.2) 
compared to archaea. Given that the interest of this study is to classify the 
groups of bacteria present in the gut of healthy controls and T2D subjects, this 
result is a positive starting point for further analysis. 
 
 
Figure 3-3: Direct sequencer data showing the kingdom 
classification of the microbial community 
 
 
 
Root;Archaea 
Root;Other 
Root;Bacteria 
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The bars represent both healthy control and T2D subjects in 
the study. Bacteria sequences (blue bar) constitutes 99.99% 
of the sequences. 
 Beta Diversity Comparisons between healthy controls and type 2 diabetes 3.6.3.
group (pre- and post-samples). 
The analysis of the microbial community by 16S rRNA gene sequencing 
using weighted UniFrac analysis of the communities showed no difference in the 
overall community diversity between the healthy controls (Red dots), T2D pre 
samples (Orange dots) and T2D post samples (blue dots). The communities had 
no separation by group (healthy controls vs T2D) or treatment (pre- vs post- 
samples) as can be seen on the PCoA plots. 
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Figure 3-4: The PCoA plot of the weighted UniFrac distances for the 16S rRNA 
analysis of DNA samples derived from healthy controls and T2D (pre and post 
samples) groups.  
No distinct difference was observed as clustering did not occur by either group (T2D 
patients and healthy controls) or treatment (Placebo and treatment).   
 70 
 Gut microbiota in healthy controls 3.6.4.
The healthy control subjects had a higher level of Bacteroidetes than 
Firmicutes (mean 54.35% versus mean 40.92%). The lowest bacteria phyla were 
cyanobacteria, Euryarchaeota and Fusobacteria (mean 0.01%, 0.01%, and 1.58e-
003% respectively) (Fig 3.4). 
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Figure 3-5: Composition of the gut microbiota in healthy controls (n=27).  
The above chart shows the composition of the gut microbiota at phyla level in healthy 
controls. The values are mean values taken from the statistical data and used to plot 
charts for visual interpretation. From the graph, the prominent four divisions are the 
phyla Firmicutes, Bacteroidetes, Proteobacteria and other. The abundance of 
Bacteroidetes is higher than that of the Firmicutes. 
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 Gut microbiota in healthy controls split by BMI- Normal weight (≤ 3.6.5.
25kg/m2) versus overweight (> 25kg/m2) 
In this study, there was a lower level of Firmicutes in overweight controls 
compared to normal weight controls (mean 37.8% versus mean 43.1%; P=0.16 and 
Q=1.0). Also, the Bacteroidetes level was higher in overweight controls compared 
to normal controls (mean 56.4% versus mean 53.1%; P=0.86 and Q=1). 
Furthermore, the level of Actinobacteria was the same for both overweight and 
normal weight controls (mean 0.16% versus mean 0.16%; P= 0.90 and Q=1), but 
the level of Proteobacteria was higher in the overweight controls than normal 
weight controls (mean 2.70% versus mean 0.76%; P= 0.96 and Q=1). However, the 
above differences were not significant for the P and Q values. 
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Figure 3-6: Difference at the phyla level between normal weight (n=14) and overweight (n=13) 
healthy controls.  
The four phyla compared between the T2D patients and healthy controls are the Firmicutes, 
Bacteroidetes, Actinobacteria and Proteobacteria. There was no significant difference between 
the normal weight and overweight group for the phylum Firmicutes, Bacteroidetes, 
Actinobacteria and Proteobacteria. 
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 Gut microbiota in T2D subjects  3.6.6.
The pre samples of T2D subjects had a higher level of Bacteroidetes 
(P=0.007; Q=0.04) and decreased level of Firmicutes (P= 003; Q=0.03) (mean 
52.54% versus mean 39.70%) (Fig 3.3). The lowest bacteria phyla were the 
Cyanobacteria, Euryarchaeota and Deferribacteres (mean 0.00%, 0.01%, and 
0.01%, respectively) (Fig 3.6). 
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Figure 3-7: Composition of the gut microbiota in T2D (n=27). 
The chart shows the composition of the gut microbiota at phyla 
level in T2D. The values are mean values taken from the statistical 
data and used to plot graphs for visual interpretation. From the 
graph, the prominent five divisions are the phyla Firmicutes, 
Bacteroidetes, Actinobacteria, Proteobacteria and other. The 
abundance of Bacteroidetes is higher than that of the Firmicutes in 
T2D subjects. 
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 Difference in gut microbiota between healthy controls and T2D (Pre-3.6.7.
samples) patients 
The Wilcoxon Signed –Rank test (Mann –Whitney test) was used to test for 
significant differences in the gut microbiota between the two groups. There was 
no significant difference between the healthy control and T2D subjects (pre) in 
the phyla Firmicutes (P=0.85; Q=0.88), Bacteroidetes (P= 0.54; Q=0.88), and 
Actinobacteria (P=0.90; Q=0.88). Reporting the p value, the phylum 
Proteobacteria was significantly different (P=0.02; Q=0.19) between the two 
groups which was higher in the T2D subjects compared to healthy controls. 
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Figure 3-8: Difference at phylum level in the gut microbiota of healthy controls 
(n=27) and T2D subjects (n=27) (pre samples).  
The bars represents the mean values taken from the statistical data and used to 
plot graphs for visual interpretation. The four phyla compared between the T2D 
patients (pre samples) and healthy controls were the phyla Firmicutes, 
Bacteroidetes, Actinobacteria and Proteobacteria. From the graph, Firmicutes and 
Bacteroidetes were slightly lower in T2D subjects compared to healthy controls. 
Actinobacteria level was low in both group but a little higher in T2D subjects. 
Proteobacteria is higher in T2D patients (pre samples) than in healthy controls. 
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 Difference in gut microbiota between healthy controls and T2D (post-3.6.8.
samples) patients 
The Wilcoxon Signed –Rank test (Mann –Whitney test) was used to test for 
significant differences in the gut microbiota between the two groups. There was a 
significant difference between the healthy control and T2D patients (post 
intervention) in the phyla Firmicutes (P=0.01; Q=0.08), Bacteroidetes (P=0.006; 
Q=0.06), and Proteobacteria (P=0.03; Q=0.11) but no significant difference for 
Actinobacteria (P=0.22; Q=0.44). GOS supplementation in the T2D patients 
resulted in higher levels of the phyla Firmicutes compared to the healthy 
controls. However, the level of Protoebacteria was higher in the T2D patients 
compared to the healthy controls.  
 
 
 
 
 77 
F ir m ic u te s B a c te r o id e te s Ac t in o b a c te r ia P r o te o b a c te r ia
0 .0
0 .2
0 .4
0 .6
     T 2 D  (P O S T  S A M P L E S ) V E R S U S  C O N T R O L
M
E
A
N
T 2 D -P O S T
C O N
p = 0 .0 1
q = 0 .0 8
p = 0 .0 0 6
q = 0 .0 6
n s
p = 0 .0 3
q = 0 .1
 
Figure 3-9: Difference at phylum level in the gut microbiota of healthy controls (n=17) and T2D 
subjects (n=26) (post samples). 
The bars represents the mean values taken from the statistical data and used to plot graphs for 
visual interpretation. The four phyla compared between the T2D patients (post samples) and 
healthy controls were the Firmicutes, Bacteroidetes, Actinobacteria and Proteobacteria. From the 
graph, Firmicutes and Bacteroidetes were higher and lower (respectively) in the T2D patients 
after GOS supplementation. Actinobacteria level was low in both groups but Proteobacteria was 
higher in T2D patients compared to the healthy controls. 
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 Gut microbiota in T2D -Placebo and prebiotic treatment group 3.6.9.
The difference between the pre and post samples of both placebo and 
treatment groups is shown below (Table 3.1). Four major phyla had either 
decreased or increased in post samples of placebo and treatment groups. For the 
placebo group, the level of Firmicutes increased in the post samples and 
Bacteroidetes level decreased. Also the level of Actinobacteria and Proteobacteria 
were increased in the post samples. For the prebiotic group, the level of 
Firmicutes and Bacteroidetes increased and decreased respectively post 
treatment, while the levels of Actinobacteria and Proteobacteria were both 
decreased. However, only the post treatment increase in the level of Firmicutes 
for the prebiotic group was significant reporting for the P and Q value, while the 
post treatment decrease of Bacteroidetes was significant reporting the P but not 
Q value (Table 3.1, Figure 3.9). Therefore, the prebiotic treatment had a 
significant effect on the gut microbiota in T2D by increasing the level of phylum 
Firmicutes. 
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Table 3-1: Mean values for the placebo and treatment group, showing the phyla mean difference 
between pre and post samples. Statistical significance were reported as P and Q values 
 
 
 
 
 
 
 
 Gut microbiota in T2D subjects – Effect of metformin treatment. 3.6.10.
The gut microbiota in T2D subjects’ taking metformin (n=18) and 
metformin naïve (n=8) showed no significant difference at the phylum level for 
Firmicutes (P= 0.51, Q=0.99), Bacteroidetes (P= 0.81, Q= 0.99), Actinobacteria 
(P= 0.58, Q=0.99) and Proteobacteria (P= 0.48, Q=0.99). However, the subjects on 
metformin had slightly higher level of Bacteroidetes (mean 54.0% versus 51.4%), 
Actinobacteria (mean 0.33% versus 0.12%), and Proteobacteria (mean 4.09% 
versus 3.20%) than those not taking metformin. Firmicutes level was higher in 
subjects’ off-metformin than those on- metformin (mean 38.5% versus 40.6%).  
 
Placebo Group 
  
Pre Post Mean diff.  P value Q value 
 
Firmicutes 39.80% 50.30% 10.50% 0.02 0.23 
 
Bacteroidetes 52.20% 42.60% -9.60% 0.07 0.28 
 
Actinobacteria 0.10% 0.20% 0.10% 0.06 0.28 
 
Proteobacteria 3.70% 3.90% 0.20% 0.56 0.89 
Treatment group  
 
Firmicutes 40.10% 48.90% 8.60% 0.001 0.02 
 
Bacteroidetes 51.50% 43.70% -7.80% 0.05 0.19 
 
Actinobacteria 0.49% 0.35% -0.14% 0.44 0.68 
 Proteobacteria 5.10% 2.50% -2.60% 0.08 0.22 
       
       
 80 
3.7. Discussion  
The primary aim of the overall study was to investigate the effects of 
prebiotic supplementation on intestinal bacteria, intestinal permeability, 
endotoxaemia, and glucose tolerance concurrently in T2D patients. To achieve 
that, intestinal permeability, anthropometric parameters, blood pressure, glucose 
tolerance, inflammatory markers and lipids were assessed at baseline and post-
interventions. The study by Pedersen et al., (2016) (see appendix A for 
publication) detailed the findings of the primary aim, where it was reported that 
prebiotic supplementation had no significant effect on clinical outcomes. 
However, for this chapter, only the effect of prebiotic supplementation on 
intestinal microbial community structure were investigated and reported [118]. 
DNA samples were sent for 16s rRNA sequencing and sequenced data files 
were statistically analysed. The sequencing yielded mainly bacteria products 
(approximately 99.99%) which make it possible to identify the bacteria groups 
residing in the gut of T2D patients and healthy controls. Looking at the 
sequenced data, over 90% of the bacteria products sequenced belonged to the 
phyla Firmicutes and Bacteroidetes, which has been reported in previous studies 
[70, 77, 79]. Furthermore, beta diversity comparisons between healthy controls 
and T2D group (pre and post samples) showed no significant difference as distinct 
clustering was not observed for groups or treatment. 
The cross sectional study analysis was to highlight the composition of the 
gut microbiota in T2D and healthy controls and differentiate between the two 
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groups. The healthy controls in this study had a higher level of Bacteroidetes 
than Firmicutes, which is contrary to the findings in the study by Larsen et al., 
2010, although the difference was not significant. Also, the healthy controls were 
split by BMI, normal weight (below 25kg/m2) versus overweight (over 25kg/m2) 
and there was no significant difference between the two groups. T2D patients 
have been reported to have higher level of Bacteroidetes than Firmicutes and 
healthy controls have higher level of Firmicutes than Bacteroidetes [75, 108]. 
This is in agreement with the present study, the T2D subjects had significantly 
higher level of Bacteroidetes (P=0.007; Q=0.04) than Firmicutes in the pre 
samples. The pre samples, which were collected before prebiotic or placebo 
treatment, serves as a true presentation of the gut microbiota in the T2D 
subjects. The level of Firmicutes were significantly lower in T2D subjects 
(P=0.003; Q=0.03). This finding is in agreement with the findings of Larsen et al. 
(2010), which showed that the diabetic group had a significantly low levels of 
Firmicutes. Also, Proteobacteria level was significantly higher in the T2D 
patients than the controls (mean 3.9% versus mean 1.7%; P= 0.01 and Q=0.19). 
This is in agreement with the findings of Mrozinska et al., (2016) and Creely et 
al., (2007) showed that at the phylum level, the amount of Proteobacteria was 
higher in the T2D group than in healthy controls [75, 119]. Therefore, this 
suggest that the gut microbiota in T2D and controls are not different, which is 
contrary to the findings of the study of Larsen et al., (2010) that reported higher 
level of Firmicutes than Bacteroidetes in healthy controls .  
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Furthermore, the Firmicutes sequence primarily belonged to the class 
Clostridia, which was higher in the T2D group than controls but not significant 
(mean 37.0 % versus mean 36.3%; P=0.47 and Q= 0.85) (see appendix). However, 
reporting the P value but not Q, the class Erysipelotrichi was significantly higher 
in the diabetic group than controls (mean 1.6% versus 1.2%; P=0.04 and Q= 0.48) 
(see appendix). The phylum Bacteroidetes was mainly presented by the class 
Bacteroidetes, which was relatively higher but not significant in the control group 
than in T2D group (mean 51.9% versus 49.1%; P=0.27 and Q=0.85) (see 
appendix). Also, the class Gammaproteobacteria, was significantly (reporting P 
but not Q values) higher in the T2D group than controls (mean 3.2% versus mean 
1.3%; P=0.02 and Q=0.48). Therefore, our findings shows that the gut microbiota 
in T2D and control subjects does not differ at the class level. 
Prebiotics have been reported as a dietary tool to remodel the gut 
microbiota, which may have secondary effects on improving glucose tolerance, 
normalising endotoxaemia, and restoring Bifidobacteria spp. levels [54]. In this 
study, the T2D group was split into prebiotic and placebo treatment groups. Each 
group had 12 weeks of supplementation with Maltodextrin or GOS. The GOS 
treatment had a significant effect on the gut microbiota in T2D by significantly 
increasing the level of the phylum Firmicutes and decreasing the phylum 
Bacteroidetes in the post samples. Although not significant, the prebiotic group 
also had higher level of Actinobacteria in the pre samples but it decreased in the 
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post samples. Also, the placebo group had low level of Actinobacteria in the pre 
samples, which increased in the post samples.  
The main importance of using GOS was due to its bifidogenic properties, 
however there was no increase in the number of bifidobacteria belonging to the 
phylum Actinobacteria, which might be attributed to dosage and/or duration of 
study, but studies in humans have shown bifidogenic effects in individuals after 
taking above 5g of GOS per day for over 10 weeks. Vulevic et al., (2008) showed 
in 44 elderly subjects randomly assigned to receive either a placebo or the B-GOS 
treatment 5.5 g/day for 10 weeks that B-GOS significantly increased the numbers 
of important bacteria, especially bifidobacteria, at the expense of less beneficial 
groups compared with both the baseline and placebo [66]. Furthermore, a similar 
study by Vulevic et al., (2013), showed that in 45 overweight adults randomly 
assigned to receive either a placebo or the B-GOS treatment 5.5 g/day for 12 
weeks, that B-GOS significantly increases the number of bifidobacteria in faeces, 
whereas decreased the number of Bacteroides spp., Desulfovibrio spp., C. 
histolyticum group and beta-Proteobacteria compared with placebo at 12 weeks 
[120]. With even much lower dosage and treatment time, thirty-seven volunteers, 
men and women of 50 years and above, included in a randomised, double-blind, 
placebo-controlled crossover trial were given juice containing 4 g GOS or placebo, 
consumed twice daily for 3 weeks found bifidobacteria that were significantly 
more abundant compared to post-placebo [121]. In addition, the method of 
analysis used in these studies may have play a role in the positive finding. 
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Methods such as FISH [66, 120] and qPCR [121] were used in the studies 
discussed above compared to 16s rRNA sequencing method used in this study. 
FISH and qPCR methods are specific for the bacteria of interest and may explain 
why these studies have positive outcomes, while 16s rRNA makes it possible to 
identify broad bacteria groups and for taxonomic purpose [122, 123]. 
Furthermore, it may be that our cohort were non-responders to GOS. To 
support this, the study by Davis et al., (2011), involving 18 healthy human 
volunteers during a 12 week period using GOS dosages administered at 
increasing levels of 0 g, 2.5 g, 5 g, and 10 g GOS per day, showed a dose 
dependent bifidogenic effect of GOS. The 2.5 g dose of GOS was not sufficient to 
induce a response, while 5 and 10 g doses induced a response. Although the 
difference between 5 and 10 g was not statistically significant, there was a 
further increase in bifidobacteria in several subjects when the dose of GOS was 
increased to 10 g. This findings points to the fact that there is a dose response 
element to GOS. In addition, it was observed that not all eighteen subjects 
showed a response of the taxa that were significantly affected by GOS. Some 
subjects responded highly to GOS, which may be due to the presence of specific 
GOS-metabolizing strains at baseline that confer responder status on that 
individual. While others who are non-responders might simply not harbour 
strains of Bifidobacteria that are able to utilize GOS [95]. 
The effect of metformin on the gut microbiota was also determined by 
comparing the composition of the gut microbiota in T2D subjects taking 
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metformin or not. T2D subjects on metformin, although not significant had 
higher level of Bacteroidetes (mean 54.0% versus 51.4%), Actinobacteria (mean 
0.33% versus 0.12%), and Proteobacteria (mean 4.09% versus 3.20%) compared to 
those not taking metformin. Firmicutes level was lower in subjects’ taking 
metformin compared to those not taking metformin (mean 38.5% versus 40.6%), 
suggesting metformin affects this taxon. Also, the T2D patients taking metformin 
had increased levels of Enterobacteriaceae compared to those not taking 
metformin (mean 3.30% versus 2.3%; P=0.02; Q=0.28). This finding is in line with 
a previous study that reported that fifty three T2D women (70 years) using 
metformin had increased levels of Enterobacteriaceae (Escherichia, Shigella, 
Klebsiella and Salmonella) and decreased levels of Clostridium and Eubacterium 
[81]. However, no significant difference was observed in our study for this 
findings as the effects of metformin were only beginning to be found after we had 
our study funded, hence we didn’t recruit based on metformin status and so 
looking at this variable would be underpowered. 
Overall, the results in this chapter suggest that the gut microbiota in 
healthy controls and T2D patients differ in the phyla Proteobacteria. Since the 
bacteria belonging to this phyla contains mostly Gram-negative species, which 
will have LPS as its outer membrane, the chances of this leading to endotoxaemia 
is high, especially if they suffer a ‘leaky gut’ [75]. Although, the placebo was also 
seen to have similar effect, GOS did improve the numbers of the phyla 
Firmicutes, which contains probiotic species that are beneficial to the host.  
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CHAPTER 4 
 
ASSESSING THE RELATIONSHIP BETWEEN 
FAECAL WATER ACTIVITY, METABOLIC 
MARKERS OF TYPE 2 DIABETES AND 
ANTHROPOMETRIC PARAMETERS 
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4. Assessing the Relationship between Faecal Water Activity, Metabolic Markers 
of Type 2 Diabetes and Anthropometric Parameters 
4.1. Introduction 
The intestinal epithelium is the largest mucosal surface that provides an 
interface with the external environment, thereby providing protection against 
foreign antigens, toxins and molecules entering the body by the oral/enteric route. 
This defensive barrier in the healthy state allows only a minimal fraction of 
antigens across, but during prematurity, or following exposure to toxins, the 
integrity of the TJ becomes compromised. This leads to the induction of an 
immune responses towards environmental antigens [100-102]. Experimentally, 
measurement of transepithelial electric resistance (TER), which is the electrical 
resistance across cellular monolayer and the ability of TJs to restrict the passage 
of small molecules such as inulin, mannitol, or dextran through the paracellular 
space are used to assess TJ barrier function [124]. In this chapter, TER was used 
to measure FW disruption of in vitro epithelial barrier function, which is a 
potentially useful non-invasive biomarker of diseases such as colorectal cancer 
and inflammatory bowel diseases. However, this has yet to be investigated in 
T2D, as a potential tool to investigate the exposure of the colonic mucosa to 
compounds which would be found in vivo and in patients, as a novel mechanistic 
discriminator between those with well managed glycaemia and those with 
uncontrolled T2D. The rationale behind this approach is that components of the 
FW fraction of faeces are more likely to have deleterious effect on the colonic 
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mucosa than substance bound to insoluble food particles or colonic bacteria [125, 
126]. Additionally, FW contains the bioactive compounds such as bile salts, 
polyphenols, SCFA and fatty acids, which may interact with stem cells at the 
base of colonic crypts. Factors such as intake of prebiotics and probiotics, drugs 
and diet have been shown to alter the activity of FW on cultured epithelial cells 
[127, 128]. This may not be the best model because the FW is not sterile. 
Synthetic FW sample that contains compounds similar to the human FW sample 
may be suitable since it can be made sterile. However, other unknown compounds 
that may be important, which are present in human FW samples will be omitted 
in the synthetic FW samples, hence using human FW samples was preferred. 
This study focuses on understanding the interaction between the gut 
microbiota and the host in T2D. To enable this understanding, this chapter 
describes the in-vitro activity of faecal water prepared ex-vivo from T2D patients 
then added to a Caco-2 cell monolayer as a model of the colonic mucosa. The aim 
was to test the hypothesis that faecal bioactive compounds will differ between 
healthy controls and T2D patients, which may have a direct impact on the gut, 
hence FW will reflect this in-vitro. Additionally, a specific aim was to determine 
whether there was any the relationship between metabolic markers of T2D, 
anthropometric parameters and the in vitro measurement of TER in the T2D 
group.  
The objectives of this chapter are to:  
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1. Investigate the effect of FW from healthy controls and T2D patients on 
Caco-2 cell monolayer integrity using a transwell and TER assay over a 
two day period. 
2. Determine the relationship between metabolic markers, anthropometric 
parameters and TER in the T2D group using linear regression analysis. 
 
4.2. Methods 
Tissue culture methods: cell enumeration, human faecal water sample 
preparation, transwells tissue culture assay, and transepithelial electric 
resistance (TER) measurements were used in this chapter as described in chapter 
2. 
 
 Anthropometric measurements 4.2.1.
Anthropometric parameters were measured non-invasively using the Tanita 
TBF-300A body composition analyser (Tanita Europe BV, Netherlands). 1.0kg 
was subtracted to allow for the weight of clothes. The Tanita TBF-300A assesses 
body composition indirectly by bioimpedence analysis (BIA) through the lower 
half of the body. A safe electrical signal is sent through the body via the pressure 
contact foot pad electrodes, which participant are asked to step onto in bare feet 
after the analyser has been switched on and calibrated. The analyser directly 
measured body weight and the bioelectric impedence using the conductive 
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properties of the legs, percentage body fat, body fat %, fat mass (kg), total body 
water (kg), free-fat mass (kg) and muscle mass (kg) are then calculated on the 
basis of the measured body weight ,bioelectric impedence and other variables 
including age, height, gender and body type.  
Height was measured using a Harpenden stadiometer without shoes, socks 
and hats. Participants stood erect, facing ahead in a horizontal plane with their 
back to the stadiometer with their heels, buttocks, shoulder blades and back of 
the head touching the wall, arms by their side, knees straight and ankles 
together. The measuring bar was lowered to touch on top of the participant’s head 
and height was recorded to the nearest 0.1cm 
 
4.3 Data analysis 
For the TER data, difference between healthy control and T2D was 
performed using two-tailed unpaired t-test. For time differences were analysed by 
one -way ANOVA, with post-hoc Tukey's multiple comparisons test. The 
relationship between monolayer integrity (TER) and metabolic markers of T2D 
were assessed using non-linear regression analysis (one phase decay). Non-linear 
regression analysis was performed using an X and Y Table format where X values 
were the independent variable (variable causing the effect) such as patient’s 
measured fasting insulin, total cholesterol, TNF alpha and LPS values, while Y 
values were the dependent variable (the variable on which the effect is observed) 
such as mean TER data for each time point for an individual patient’s FW 
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sample. The use of this approach was discussed with a statistician in the 
Mathematics Department at the University of Surrey (Peter Williams) and he 
noted that the sampling number was small, but the r2 and p2 values should be 
used as an indicator of how good the model fits is. The statistical significance is 
represented as R2 (denotes goodness of the slope fit) and P value (≤ 0.05). P ≤ 0.05 
was considered statistically significant. Al statistical analysis were performed 
using Prism 7 GraphPad software. 
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4.4 Results 
4.4.1 Faecal water samples from type 2 diabetes patients had significant effect 
on cell monolayer integrity 
 
When compared with the FW samples of healthy controls, the T2D patients 
FW samples had significant impact on cell monolayer integrity as TER were 
decreased at 24 hours and 48 hours post treatment (Figure 4.1) (p=<0.001 and 
p=0.003, respectively), but not at 0 hour (baseline)(p=0.8745).  
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Figure 4-1: FW from T2D patients (n=9) at 24 and 48 hours (b and c respectively) had 
significant impact on TER compared to FW samples from non-diabetic healthy controls 
(n=3).  
At baseline, TER for healthy controls and T2D group were not significantly different. At 
24 and 48 hours, FW samples from T2D patients significantly decreased TER 
(p=<0.0001 and p= 0.03 respectively). The values are expressed as percentage of 
negative control (without FW set as 100% TER integrity). The data represents the mean 
± SEM of at least three independent experiments. Two tailed unpaired t test. P ≤ 0.05 
 
 
A B C 
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4.4.2 Type 2 diabetes patients’ faecal water samples reduced cell monolayer 
integrity in a time- dependent manner 
 
Caco-2 cell monolayer grown on transwell inserts on the apical 
compartment were challenged with FW from 9 T2D patients. The experiment was 
performed over a 24 hours periods with TER readings taken at 0, 12 and 24 
hours. The results showed that FW samples had a significant impact on cell 
monolayer integrity as TER decreased in a time dependent manner. At the start 
of the experiment, TER remained unchanged for 8 out of 9 samples (Figure 4.2 b-
I), while 1 sample significantly decreased TER (-27.76%, p=0.0072) (Figure 4.2a) 
compared to the TER before treatment (initial TER) with FW sample. However, 
compared to the TER at 0 hour, 7 out of 9 samples significantly reduced TER at 
24 hours (-41.95%, p= 0.0005; -45.91%,p=0.0041; 43.48%,p=0.0124; -
44.02%,p=0.0134; -46.87%, p=<0.001; -59.97%, p=0.01; and-54.21, p=0.03) and 48 
hours (-38.61% ,p= 0.0009; -13.9%,p= 0.4559; -31.33%,p= 0.0626; -18.76%,p= 
0.3501; -32.55%, p= 0.0012; -78.87 ,p= 0.003; and -59.32, p= 0.0183) (Figure 4.2 a-
f, I ) but the extent varied between different patient samples. The extent of TER 
increase or decrease is shown in Table 4.1. 
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Figure 4-2: Effect of faecal water on transepithelial resistance. 
FW samples from T2D patients (n=7, a-i) had an effect on TER causing decrease in a time 
dependent manner. The values are expressed as percentage of control (without FW). The data 
represents the mean ± SEM of three independent experiments. ^,* and #, denotes, statistical 
significance to initial, 0 hour and, 24 hours respectively. P ≤ 0.05 ANOVA followed by Tukey's 
multiple comparisons test. 
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Table 4-1: TER % increase/ decrease for T2D faecal water sample.  
These values are for FW sample in samples represented in Figure 4.2 with the label 
shown in the serial number A-I (s/n) below. All values are comparison with 0 hour unless 
otherwise stated. 
 
 
 
 
 
 
 
a Comparion with Initial TER  
b Comparison with 24 hours 
 
4.4.3 Association of in-vivo metabolic markers of type 2 diabetes with faecal 
water activity in-vitro 
 
Non-linear regression was used to assess the relationship between in-vivo 
markers of T2D and the FW samples (n=5) impact on cell monolayer integrity. 
The range of means for the markers of T2D for all patients is shown in Table 4.3. 
The TER means for 0, 24 and 48 hours for all samples were used in a linear 
regression model with patient values for insulin, total cholesterol, LPS and TNF 
 
TER % Increase/decrease 
S/N 0 Houra  P value 24 Hours P value 48 Hours P value 48 Hoursb P value 
A -27.76 0.0072 -41.98 0.0005 -38.61 0.0009 3.34 0.9417 
B -17.8 0.2708 -45.91 0.0041 -13.9 0.4559 32.01 0.0303 
C -4.76 0.9642 -43.48 0.0124 -31.33 0.0626 12.12 0.6544 
D -13.82 0.5834 -44.02 0.0134 -18.76 0.3501 25.26 0.1566 
E -10.85 0.1447 -46.87 <0.0001 -32.55 0.0012 14.32 0.0977 
F 13.76 0.8447 -59.97 0.015 -78.87 0.003 -15.09 0.8062 
G 0.11 >0.9999 -28.74 0.2505 -29.48 0.2319 0.76 >0.9999 
H 7.76 0.9721 -29.81 0.2505 -32.72 0.3142 2.91 0.9984 
I 10.79 0.9721 -54.21 0.0313 -59.32 0.0183 -5.11 0.9896 
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alpha, with the r2 and p values shown below (Table 4.3). At baseline, only one 
sample (Figure 4.2.a.) had an effect on TER, which significantly decreased TER 
compared to the initial (pre-faecal water addition) TER. The sample was from a 
T2D patient who had significant hyperinsulinaemia (213.5 pmol/L fasting 
insulin) compared to other patients (Figure 4.2 b-e). At 24 hours of FW 
incubation, all samples had significantly decreased TER to approximately 27-47 
% of control TER, which was significantly associated with elevated plasma total 
cholesterol and TNF alpha (Figure 4.2 a-e). However, compared to the TER 
measured after 24 hours of incubation, the TER actually increased for all samples 
by 48 hours of incubation (Table 4.1) but the extent varied among patient 
samples and was only significant for one T2D patient (Figure 4.4b.). The TER 
increase was inversely associated with the level of plasma LPS (Figure 4.6), with 
one patient’s FW sample having the lowest TER increase and highest LPS level 
(+3.34% and 4.45 EU/ml) compared to other T2D patient samples (Figure 4.2a, 
Table 4.3). 
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Table 4-2 Mean Values of metabolic markers for T2D patients 
 
Table 4-3: Non-Linear regression analysis assessed the relationship between TER 
(mean of 3 values per patient) and metabolic markers in T2D patients. The R2 value for 
0, 24 and 48 hours are presented (n=5) 
.
 T2D patients mean 
values 
 Range 
N 5   
Insulin(pmol/L) 98.79  44.214- 
Total Cholesterol (mmol/L) 4.53  3.6 – 5.4 
LPS (EU/ml) 1.598  0.3 – 4.5 
TNF-a (pg/ml) 25.57  13.48 
TIME (hours) 0  24  48  
 R2 Value  R2 Value  R2 value 
Insulin(pmol/L) 0.8978  -  - 
Total Cholesterol 
(mmol/L) 
-  0.7735  - 
LPS (EU/ml) -  -  0.8521 
TNF-a (pg/ml) -  0.9427  - 
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Figure 4-3: Regression analysis assessed the relationshp betweeen the TER (48hours) and 
Clinical parameters. 
The TER mean values of the T2D patients (n=5) for three independent transwell experiments 
were used in a non-linear regression model with patients’ blood measurements of Insulin, 
total cholesterol, TNF alpha and LPS at A) 0 hour B) 24 hour and C) 48hour. The decrease in 
TER associated with increasing levels of A) insulin in the T2D patients. While a saturation 
effect was observed between TER and B) total cholesterol C) TNFa and D) LPS, where the 
decrease in TER occurred with low concentrations and remained stable as the concentration 
increased. 
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4.4.4 Anthropometric parameters of type 2 diabetes patients associated with 
faecal water decrease of cell monolayer integrity. 
 
Linear regression was used to assess the relationship between 
anthropometric measurements of T2D patients and the FW (n=4, Figure 4.2 F-I) 
impact on cell monolayer integrity. Anthropometric parameters were measured 
for four T2D patients (Figure 4.2 F-I), which was used in a linear regression with 
means of TER values (3 independent experiment). The TER means for 0, 24 and 
48 hours for all samples were used in a linear regression model with age, body 
weight, BMI, body fat %, fat mass (kg), total body water (kg), free-fat mass (kg) 
and muscle mass (kg). The r2 and p values are shown in Figure 4.7. At 24 hours, 
two FW samples (fig 4.2 a & d) significantly decreased TER which was 
significantly associated with elevated level of body fat % and decreased level of 
total body water (Figure 4.4 a & b). Additionally at 48 hours, TER decreased for 2 
samples which was associated with elevated level of body fat % and decreased 
level of total body water (Figure 4.7 c& d; 4.4 c & d).  
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Figure 4-4: Linear regression analysis assess the relationship between TER (24hours, a-b; 48 
hours, c-d) and anthropometric parameters of T2D patients. 
The TER mean values of the T2D patients (n=4) for three independent transwell experiments 
were used in a linear regression model with age, weight, body mass index, body fat %, fat mass 
(kg), total body water (kg),free fat mass (kg) and muscle (kg) measured using the bioimpedence. 
The decrease in TER associated significantly with high body fat % and low total body water in 
the T2D patients at 24 and 48 hours. R2 and p values are displayed on the Figures. 
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4.5 Discussion 
Tight junctions protect the body from passage of harmful substances across 
the intestinal barrier. The concept of ‘leaky gut’ in human T2D had previously 
been investigated but the exact mechanism is not known. However, high-fat diet 
and gut microbiota has been thought to play a role by altering its composition 
favouring growth of bad bacteria over good bacteria. The overgrowth of Gram-
negative bacteria in turn disrupts the tight junctions by producing harmful 
metabolites which negatively impact the integrity of the epithelial cell monolayer 
[129-131]. 
It was hypothesised that the FW samples from healthy controls will not 
decrease cell monolayer integrity, which maybe a related to non-diseased state. 
The healthy controls FW samples did not significantly decrease cell monolayer 
integrity, although very few samples were used, which may not be representative 
of healthy states. These findings was also observed in another study [125], where 
two FW samples from healthy controls did not change Caco-2 TER over a 24 
hours period. This may suggest that in contrast to T2D, the observed effect on cell 
monolayer integrity by the FW from healthy controls likely indicates it is 
dependent of disease state and associated with elevated levels of insulin in T2D. 
Also, the impact of individual T2D patients FW on TER over a 48 hours period 
was investigated and it was observed that 77% (7 out of 9 samples) of FW 
samples from T2D patients had significant impact on TER at 24 hours, with TER 
increase noticed at 48 hours for most samples (7 out of 9 samples). To 
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demonstrate that the in vitro FW activity (n=5) of the T2D patient’s may likely be 
associated with the physiological aspects of the condition, we used non-linear 
regression (one phase decay) to assess the relationship between TER (assessed at 
different time points) and markers of T2D.This suggests a possible saturation 
effect as the decrease in TER appears to occur rapidly at low concentration of 
total cholesterol (r2= 0.7715), TNF alpha (r2=0.8670), and LPS (r2= 0.8346) , with 
a steady state as the concentration increased. However the decreased TER seems 
to be decreasing as the insulin concentration increased. All markers had over 
70% relationship with decreased TER, which may suggests that metabolic state of 
T2D patients may possibly play a role in the activity of FW in-vitro. Furthermore, 
linear regression assessed the relationship between TER of FW of T2D patients 
(n=4) and anthropometric parameters, which showed that TER decrease at 24 
and 48 hours was associated with higher body fat % and lower total body water 
(kg).  
This study identified FW activity might help explain physiological features 
of the condition, although further investigation as to the underlying mechanism 
is needed. One possibility is that T2D impacts upon the gut microbiota and its 
metabolites such as SCFA, LPS, bile acids and TNF alpha, which may determine 
the FW activity in-vitro, assuming that the plasma level may reflect the faecal 
level of these bacterial metabolites. Prior to faecal sample collection, the T2D 
patients had no prebiotic and probiotic intake, therefore the two likely patient 
activities that can affect the FW components used in this study are diet and use 
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of drugs such as metformin and NSAIDs. These factors had been previously 
shown to affect the FW activity on cultured cells such as Caco-2 causing 
genotoxic, cytotoxic and apoptotic effects [128, 132, 133] and preventing bacterial 
cell adhesion to cells [134].  
Whilst the present study didn’t investigate the components of the FW from 
T2D patients, it has been previously shown that FW activity can be altered by 
diet high in fat [137], high calcium [138], high protein, red meat and 
carbohydrate [139, 140], dietary meat and fish [141], dietary copper [142], high 
concentration of bile acids [143], vegetables (carrot and tomatoes) [144], and 
prebiotics [135, 136]. Bacterial metabolites such as SCFA, bile acids, LPS, TNF 
alpha, phenols and ammonia play a role in determining barrier function using 
epithelial cell culture models such as Caco-2 and T84. A study of diet on the 
cellular toxicity of FW, identified bile acids and fatty acids as the major 
compounds responsible for the activity of FW on cultured colonic cells. This study 
included 18 healthy male and females, who were involved in a cross over study 
where they changed from a dairy –rich diet to a diary –free diet [126].  
Primary bile acids (cholic acid and chenodeoxycholic acid) are metabolised 
in the liver from cholesterol and the gut flora in the colon then hydroxylate them 
to secondary bile acids (mainly deoxycholic acid and lithocholic acid). These 
secondary bile acids cause DNA damage and apoptosis to cultured cells, which 
links the gut microbiota to colon pathogenesis [48, 127]. Assuming that the level 
of total cholesterol observed in T2D patients (n=5) , could possibly lead to the 
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metabolism of primary bile acids, which the gut microbiota may convert to 
secondary bile acids and may potentially be present in high levels in the patients 
faecal samples. This may explain why cholesterol was associated with a decrease 
in TER after 24 hours of incubation with FW samples from T2D patients. Another 
study also observed bile acid reduction in TER in a time-dose dependent manner 
when added directly to the cell model. Bile acids were used at concentration that 
were physiologically relevant to the faecal aqueous concentrations (200µM). All 
bile acids reduced TER but cholic acid and hyodeoxycholic acids strongly 
decreased TER, which were due to alteration in metabolic energy, protein 
synthesis or transcription in Caco-2 cells [137] . 
Also, at 24 hours after incubation with faecal water samples from T2D 
patients, the drop in TER was associated with high TNF alpha and it has been 
previously shown to affect epithelial cell monolayer integrity. The addition of 
TNF-α (5 ng/ml), when Caco-2 monolayers were preconditioned for 24 h with IFN-
γ (10 ng/ml) induced the expression of TNF-α receptors and caused a significant 
drop in TER within 6 h [138] . Additionally, Caco-2 cells displayed decreased TER 
of the cell monolayer when treated with TNF alpha for 6 h and the TER of Caco-2 
cells dropped to the lowest level after stimulation by TNF-α for 48 h when 
compared to the baseline. Also, further incubation for 96 h, showed that TNF 
alpha induced changes on the TER of Caco-2 cells could not be reversed. This was 
due to TNF alpha in Caco-2 cells initiating NF-κB activity (lasted for 24 hours), 
cells exhibiting paracellular gaps between epithelial cells after 6 h of TNF-α 
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treatment, induced stress fibre formation and sizeable gaps after Caco-2 cells 
stimulated by TNF-α for 24 h and were worsened after 48 h of TNF-a treatment. 
Finally. decreased cellular protein levels of ZO-1 was observed after treated by 
TNF-α for 6 h, while the down-regulation of occludin occurred much more lately 
and inhibition of NF-κB reversed the loss of tight junction proteins [139]. Another 
study investigated the effect of TNF alpha induced intestinal epithelial barrier 
dysfunction in Caco-2 cell monolayer and the underlying mechanism. Caco-2 
monolayers treated with 100ng/ml TNF alpha for 72hours caused reduced TER 
and increased phenol red flux. This was due to the distribution of occluding and 
ZO-3, which were broken and fluorescence intensity was weak. Also, the NFkB 
signalling pathway was activated when Caco-2 cell monolayers were exposed to 
100ng/ml TNFalpha for 12hours [140]. The above studies indicates that decreased 
TER caused by TNF alpha occur in a time dependent manner, hence the 
incubation time used in the present study (0-48 hours) made it possible to observe 
the effect, which was linked with the level of TNF alpha in FW at 24 hours . Also, 
inferring from the above studies mentioned, the possible mechanism of action of 
TNF alpha in FW of T2D patients used in this study might be disruption of TJ 
and activation of the NFkb pathways.  
The drop in TER at 48 hours after incubation was associated with LPS. 
There was an increase in TER at this time point but only one sample had a lesser 
increase compared to other T2D patients and this patient had higher level of LPS 
compared to other patients. Assuming that high level of serum LPS could imply 
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high faecal LPS, it can potentially be due to LPS impact on cell monolayer 
integrity. In agreement with our findings, TER of Caco-2 cell monolayer pre-
treated with LPS for 48 hours was significantly decreased [141]. Similarly, LPS 
significantly decreased TER when Caco-2 cells were treated with LPS for 24 
hours [142]. LPS added to the basolateral but not apical side of Caco-2 cell 
monolayer caused a significant decrease in TER and increased penetration of FD-
4 across the monolayers after a 2 hours treatment [143] . Likewise, TER was 
consistently decreased in LPS induced cells at 1, 3, 6 and 12 hours [144]. Also 
LPS at clinically relevant concentrations (1, 5, 10 ng/ml) significantly reduced 
TER after day 4 [145]. The above findings highlights the relevance of incubation 
time in the action of LPS as the time ranged from 1 hour to 7days, which may 
suggest that the LPS in FW of T2D patients used in the present study took effect 
at 48 hours post incubation possibly due to the LPS concentration present in the 
FW. In addition, the possible mode of action of the LPS in FW in disrupting 
barrier function by decreasing TER, could be by inducing cell inflammation by 
increased production of pro-inflammatory cytokines (such as IL-1beta, TNF 
alpha, 1L-6, 1L-8) and decreased anti-inflammatory cytokines (such as IL-10) 
[141, 142, 144, 146-148]. Also LPS in FW could have decreased cell viability by 
acting as an anti-proliferating agent and increase oxidative stress, which can 
induce cell apoptosis by directly damage cell membrane or important genetic 
material [142]. Lastly, LPS in FW could induce reduced expression and 
redistribution of tight junction proteins (such as occludin, ZO-1 and claudins), 
and NFkB activation in Caco-2 cells [142, 144, 145, 147, 149-151]. 
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Furthermore, although the cohort in this study was divided by disease 
state, healthy controls and T2D, SCFA may potentially differ between the two 
groups, hence the FW from healthy controls had no significant impact on TER. 
The role of SCFA contained in FW in maintaining barrier function was 
investigated in a study to assess the factor of age as a major risk factor for 
colorectal cancer [152]. The findings from the study by Gill et al., (2007) showed 
that treatment of Caco-2 cells with FW samples had significant impact on TER 
over a 48 hours period, as FW from adults increased TER (+ 4%), whereas FW 
from elderly subjects decreased TER (−5%). Also, their findings showed several 
components of FW potentially associated with modulation of TER, namely, SCFA 
and ammonia were investigated and SCFAs (propionic, acetic, and n-butyric) 
were significantly lower in the elderly population (−30%, −35%, and −21%, 
respectively). Likewise the effect of SCFA on barrier function was determined in-
vitro, and the result showed that SCFA mixture improved TER at 24 hours but 
abated at 48 hours. However, SCFA used individually did not improve TER at 
any time point [152].  
Although this study presents a pilot character, it is a novel idea as to the 
use of FW in-vitro to differentiate between disease state, how well managed it is 
in a person, and it needs to be further studied in a large cohort. This approach 
could serve as a non-invasive quick screen that can be done with faecal samples 
in-vitro to speculate on how well the disease was managed long term. Although 
permeability assay was not performed to determine whether the extent of the FW 
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impact can lead to cell monolayer permeation of solutes, but it is likely that 
continuous decreased cell monolayer integrity will be harmful to barrier function.  
Most studies extract a compound of interest and test it using this model of 
barrier function but this study has used FW as a possible representation of the 
colonic content consisting of compounds from both human and bacteria. 
Therefore, this study represents a novel in-vitro model and human in-vivo 
markers are needed to better explain this concept. The correlation between the 
Caco-2 cells decrease in TER and in-vivo markers of T2D could be because the gut 
is the common source of components such as inflammatory mediators and 
endotoxins. Also, ‘live gut bacteria’ has been found in the blood of T2D patients 
[153] , hence, it is likely that plasma and faeces may be similar in content and 
concentration.  
In future studies, to best suit the human situation, it may be ideal to 
perform the experiments within a 24-hour duration as the time point to 
determine the optimal effect of FW on Caco-2 cell monolayer integrity. This is 
because an increase in TER was observed at 48 hours post incubation with most 
FW samples. It has been shown that inflammatory mediators such as TNF alpha, 
induced the release of acute phase proteins such as LPS binding protein (LBP) 
and Serum amyloid A (SAA) by intestinal epithelial cells such as Caco-2, which 
indicates that tissues other than the liver are in involved in the acute phase 
response and play an important role in the local inflammatory process in the gut 
[154]. Therefore, incubation with FW for over 24 hours may not be relevant as the 
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cells may have released LBP and SAA into circulation in local defence against 
endotoxins such as LPS. Although this depends on the local concentration of LBP, 
for most FW samples, the toxicity of endotoxins will be greatly reduced, hence 
variable outcome may be observed at time points over 24 hours. In addition, the 
faeces contains compounds from the colon, and the normal colon transit of 24 
hours is reflected by activity in the right colon [155, 156], hence the colon mucosa 
will be in contact with the content of the colon for approximately 24 hours and 
this time point may best explain the difference between healthy controls and 
diseased state as well as the management of diseased state.  
The limitation of this study was the few FW samples used especially from 
the healthy control group (n=3), but in the future where more FW samples are 
used in similar studies, the proposed ideal incubation time will be 24hours. 
  
 110 
 
CHAPTER 5 
 
 
NON-PREBIOTIC EFFECT OF GOS AGAINST 
FAECAL WATER CYTOTOXICITY 
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5 NON-PREBIOTIC EFFECT OF GOS AGAINST FAECAL WATER 
CYTOTOXICITY 
5.1 Introduction 
The effect of prebiotic via the action of the gut microbiota has been 
previously studied both in vivo and in vitro [71, 89, 157], however the non-
bacteria effect of prebiotic has also been investigated [158]. The work described in 
this chapter focused on investigating the faecal sample cytokine profile, 
cytotoxicity of FW samples, and the effect of the prebiotic GOS on FW Caco-2 cell 
cytotoxicity. Although the source of the cytokines present in the faecal samples 
used in this study was not established, it is known that the adipose tissue, liver, 
muscle and the pancreas are sites of inflammation in the presence of T2D and the 
production of pro-inflammatory cytokines including IL-6, IL-1Beta and TNF 
alpha are produced at these sites [159].  
Pro -inflammatory cytokines promote insulin resistance in an autocrine 
and paracrine manner by interfering with insulin signalling in peripheral tissues 
through the activation of c-JUN N-terminal kinase (JNK and nuclear factor-
Kappa B (NFkB) pathways [160]. In T2D, these pathways are activated in 
multiples tissues and play a central role in promoting tissue inflammation [159, 
161-163]. 
FW cytotoxicity has been previously studied, by a number of researchers 
and they focused on the impact of diet consumed in healthy volunteers [126, 132, 
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164, 165]. However, FW cytotoxicity has not yet been explored as a potential 
biomarker for diseases such as T2D, where low-grade inflammation is known to 
play a major role in disease progression.  
The aims of this study were as follows; 
i) Investigate the cytokine profile of T2D patients using a non-invasive 
sample and  
ii) To elucidate the impact of FW samples as a complex inflammation 
mixture on cytotoxicity in a caco-2 cell model. 
The specific objectives of this chapter were to: 
1. Investigate the faecal cytokine profile using faecal protein extracted 
from T2D patient’s faecal samples in a human cytokine array. 
2. Investigate the effect of GOS on Caco-2 cell viability using MTS 
assay 
3. Investigate the FW cytotoxic effect on Caco-2 using MTS assay 
4.  Investigate the potential protective or preventive effect of GOS on 
Caco-2 cells in a presence/absence assay using MTS assay. 
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5.2 Methods 
The methods used in this chapter includes faecal protein extraction, 
determination of protein concentration, cytokine array and cell viability assay to 
measure faecal water cytotoxicity, GOS preparation and MTS assay as described 
in chapter 2. 
 
5.3 Results 
5.3.1 Pro and anti- inflammatory cytokines measured in type 2 diabetes patients 
faecal samples 
The detection of a broad spectrum of cytokines in human faecal samples 
(n=4) was assessed in faecal protein medium using the RayBio Human Cytokine 
Antibody Array 1 analysis. Figures 5.1 and 5.2 demonstrates cytokine levels 
expressed as a percentage of the positive control of the array (set as 100%). The 
positive control was a controlled amount of biotinylated antibody printed onto the 
array. All of the 23 selected cytokines (Figure 2.1) were detected in all FW 
samples (Figure 5.1). TNF-alpha and TNF–beta were lower in all samples. In 
addition, anti-inflammatory cytokines such as IL-13, TGF- beta 1 and IL-10 were 
detected in all patients’ samples 
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Figure 5-1: Measurement of 23 cytokines in faeces of human T2D patients (n=4) using the RayBio 
Human Cytokine Antibody Array 1.  
Faecal protein were used to determine the cytokine present in the T2D patients’ faecal samples 
and all 23 cytokines were detected. Data are expressed in % versus the positive control of the 
array (100%) used for normalization and to orientate the arrays. The data represents the mean ± 
SEM of duplicates of two independent experiments.  
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5.3.2 Cytokines that differed between individual type 2 diabetes patients 
The cytokines IL-6, G-CSF , IL-1alpha , IL-2, IL-3 IL-15, IFN-gamma , 
RANTES , TGF-beta 1 , IL-7, IL-8 and IL-13 were either significantly higher or 
lower between patients (Figure 5.2 and 5.3 ). Furthermore, typical triggers of 
inflammation in T2D such as IL-6 and RANTES varied between individuals.  
Patient 1 had significantly higher levels of IL-6 (p=0.0124, Fig 5.2a), IL-3 
(p=0.0328, Fig 5.2c), IL-8 (p=0.0466, Fig 5.3e) and IL-13 (p=0.0264, Fig 5.3f) 
when compared to patient 3. Also, patient 2 had significantly higher levels of IL-2 
(p=0.0406, Fig 5.2d) and RANTES (p=0.0212, Fig 5.3b), when compared to patient 
3. Likewise, patient 3 had significantly higher levels of G-CSF (p=<0.0001; Fig 
5.2b), TGF-beta1 (p=0.0001, <0.0001 and <0.0001 respectively; fig 5.3c) and IL-1 
alpha (p= <0.001, 0.0284 and 0.001 respectively; fig 5.2c) when compared to 
patient 1, 2 and 4, IL-15 (p=0.0030 and 0.0003 respectively; fig 5.2f) when 
compared to patient 1 and 4. Finally, patient 4 had significantly higher levels of 
IL-6 (p=0.0169), IFNg (p=0.0134), IL-7(p=0. 0212), and IL-13 (p=0.0284) when 
compared to patient 3. 
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Figure 5-2: Measurement of inflammatory cytokines IL-6 (A) G_CSF (B), IL-alpha (C) IL-2 (D), 
IL-3 (E) and IL-15 (F) in faecal sample from T2D patients (patients 1-4) (n=4) (RayBio Human 
cytokine Antibody Array 1 analysis).  
The above cytokines were significantly different between T2D patients. Data are expressed in 
% versus the positive control of the array (100%). The data represents the mean ± SEM of 
duplicates of two independent experiments. ****p= < 0.0001, ***p= < 0.001, **p=<0.01 *p=< 
0.05 ANOVA followed by Tukey's multiple comparisons test.  
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Figure 5-3: Figure 5-3: Measurement of inflammatory cytokines IFN-gamma (A) RANTES (B), 
TGF-beta (C), IL-7 (D), IL-8 (E) and IL-13 (F) in faecal samples from T2D patients (patient 1-
4) (n=4) (rayBio Human Cytokines Antibidy Array 1 analysis).  
The above cytokines were significantly different between individual T2D patients. Data are 
expressed in % versus the positive control of the array (100%). The data represents the mean 
± SEM of two independent experiments. ****p= < 0.0001, *p=< 0.05 ANOVA followed by 
Tukey's multiple comparisons test.  
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5.3.3 Bimuno galactooligosaccharide and Caco-2 cell viability 
To determine whether B-GOS altered cell viability, Caco-2 cells were 
incubated in the presence and absence of B-GOS for 2 and 12 hours. The different 
volume/ volume (v/v) concentrations of GOS was prepared in cell culture media 
from the weight/volume B-GOS preparation. At 2 hours post-incubation, 10% and 
15% cell viability was not significantly decreased when compared to the 
untreated control. Treatment with 5% v/v significantly increased cell viability 
compared to control, 10% and 15% v/v B-GOS treatment (Fig 5.5 A). Also, at 12 
hours post-incubation, 5% and 10% v/v B-GOS treatment significantly increased 
cell viability compared to control and 15% v/v B-GOS treatment (Fig 5.4 B).  
 
 119 
 
Figure 5-4: Galacto-oligosaccharide did not decrease cell viability.  
Cells were pre-treated with 5%, 10% and 15% (v/v) GOS for A) 2 hours and B) 12 
hours. Cell viability was measured using MTS assay after the incubation with GOS. 
GOS did not significantly reduce cell viability after 2 and 12 hours, but increased 
cell viability compared to control. The values are expressed as percentage of control, 
without GOS which was used as 100% cell viability. The data represents the mean ± 
SEM of triplicates of six independent experiments. **p=<0.01, ***p= < 0.001 
ANOVA followed by Tukey's multiple comparisons test 
 
5.3.4 Cytotoxic effect of type 2 diabetes FW samples on Caco-2 cells 
To determine the cytotoxicity of FW samples, Caco-2 cells were incubated 
with FW for 2 hours and cell viability was assessed using MTS assay. Two 
samples were cytotoxic to cells post-incubation, which significantly decreased cell 
viability to 42% (Figure 5.5 a) and 43% (Figure 5.5 d) of the non-infected control. 
However, 2 samples were not cytotoxic to cells as no significant cell viability was 
observed and were 83% and 85% of the negative/non-infected control (Figure 5.5 
b& c). 
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Figure 5-5: Effect of FW from Type 2 diabetes patient on cell viability. 
Cell viability was measured using MTS assay after Caco-2 cells were challenged with 
FW for 2 hours. FW of patient 1 A) and patient 4 D) significantly reduced cell viability 
of Caco-2 cells. The value expressed as percentage of control (without FW) which was 
used as 100% cell viability. The data represents the mean ± SEM of triplicates of nine 
independent experiments. **** p=< 0.0001ANOVA followed by Tukey's multiple 
comparisons test. 
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manner. Pre-treatment of cells with B-GOS at 5%, 10%, and 15% was performed 
for a duration of 2 and 12 hours either in the presence or absence of B-GOS when 
incubated with FW for 2hours.  
 
5.3.5.1 Two-hour pre-treatment with galactooligosaccharide before FW 
cytotoxicity assay:  
5.3.5.1.1 Type 2 diabetes patient 1 
For sample 1, the result showed that cells pre-treated with B-GOS for 2 
hours , followed by incubation for 2 hours with FW in the presence of B-GOS 
increased cell viability from 42% of the non-infected control ( Figure 5. 5a) to 99%, 
93%, and 73% of the control for 5% , 10% and 15% v/v concentration respectively 
(Figure 5.6 a). Incubation of cells with FW in the absence of B-GOS caused 
significant decrease in cell viability (p= < 0.05) to 53%, 54% and 46% of the 
control for 5%, 10% and 15% v/v concentration, respectively compared to the 
control (Figure 5.6 b).  
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Figure 5-6: Figure 5-6: The effect of FW on cell viability in the presence or absence of 
GOS (patient 1).  
Cells were pre-treated with 5%, 10% and 15% (v/v) GOS for 2 hours and cells were then 
incubated with FW for additional 2 hours a) in the presences of GOS and b) in the 
absence of GOS. Cell viability was measured using MTS assay after incubation with 
FW. FW did not significantly reduce cell viability (p = < 0.05) in the presence of GOS, 
but did decrease cell viability in the absence of GOS. The values are expressed as 
percentage of control, without FW which was used as 100% cell viability. The data 
represents the mean ± SEM of three independent experiments. ****p= < 0.0001 
ANOVA followed by Tukey's multiple comparisons test. 
 
5.3.5.1.2 Type 2 diabetes patient 2 
The result showed that cells pre-treated with B-GOS for 2 hours, followed 
by further incubation for 2 hours with FW in the presence of B-GOS, resulted in 
increased cell viability from 83% of the non-infected control (Figure 5.5 b) to 87%, 
119%, and 72% of the negative control for 5%, 10% and 15% v/v concentrations 
respectively (Figure 5. 7 a). Also, in the presence of B-GOS, the 15% v/v 
B A 
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concentration significantly decreased cell viability (p= < 0.05) compared to 10% 
v/v. However, the incubation of cells with FW in the absence of B-GOS had no 
significant effect on cell viability as it was 94%, 100% and 92% of the control for 
5%, 10% and 15% v/v concentration respectively (Figure 5.7 b). Also, in the 
absence of B-GOS, the cell viability was not reduced as it was 94%, 100% and 
92% of control.  
 
Figure 5-7: The effect of FW on cell viability in the prescence or absence of GOS 
(patient 2).  
Cells were pre-treated with 5% ,10% and 15% (v/v) GOS for 2hours and cells were 
incubated with FW for additional 2 hours in a) in the presences of GOS and b) in the 
absence of GOS. Cell viability was measured using MTS assay after the incubation 
with FW. FW did not significantly reduce cell viability (p= <0.05) in the presence 
and absence of GOS. The values are expressed as percentage of control (without FW) 
which was used as 100% cell viability. The data represents the mean ± SEM of three 
independent experiments. *p= < 0.05, not significant p=> 0.05 ANOVA followed by 
Tukey's multiple comparisons test. 
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5.3.5.1.3 Type 2 diabetes patient 3 
For patient 3, the result showed that cells pre-treated with B-GOS for 2 
hours, followed by incubation for 2 hours with FW in the presence of B-GOS 
resulted in increased cell viability from 85% of the non-infected control (Figure 
5.5 c) to 135%, 116%, and 81% of the control for 5%, 10% and 15% v/v B-GOS 
respectively (Figure 5.8 a). Also, in the presence of B-GOS, 15% v/v concentration 
significantly decreased cell viability (p= < 0.05) compared to 10% v/v. However, 
the incubation of cells with FW in the absence of B-GOS had no significant effect 
on cell viability as it was 94%, 100% and 92% of the control for 5%, 10% and 15% 
v/v concentration respectively (Figure 5.8 b). Also, in the absence of B-GOS, the 
cell viability that was significantly decreased for 15% v/v B- GOS compared to 
10% v/v B-GOS was reversed as B-GOS absence during incubation with FW was 
beneficial to cells. 
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Figure 5-8: The effect of FW on cell viability in the presence or absence of GOS 
(patient 3).  
Cells were pre-treated with 5% ,10% and 15% (v/v) GOS for 2hours and cells were 
incubated with FW for additional 2 hours in a) in the presences of GOS and b) in the 
absence of GOS. Cell viability was measured using MTS assay after the incubation 
with FW. FW did not significantly reduce cell viability (p=> 0.05) in the presence 
and absence of GOS. The values are expressed as percentage of control (without FW) 
which was used as 100% cell viability. The data represents the mean ± SEM of three 
independent. *p= < 0.05, not significant= p>0.05 ANOVA followed by Tukey's 
multiple comparisons test. 
 
5.3.5.1.4 Type 2 diabetes patient 4  
For sample 4 , the result showed that cells pre-treated with B-GOS for 2 
hours, followed by incubation for 2 hours with FW in the presence of B-GOS 
increased cell viability from 43% of the non-infected control ( Figure 5.5 D) to 
85%, 80%, and 61% of the control for 5% , 10% and 15% v/v concentrations 
respectively (Figure 5.9 A). Otherwise, the incubation of cells with FW in the 
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absence of B-GOS caused significant decrease in cell viability (p= < 0.05) to 53%, 
42% and 42% of the control for 5%, 10% and 15% v/v concentration, respectively 
when compared to the non-infected control (Figure 5.9B).  
 
Figure 5-9: The effect of FW on cell viability in the prescence or absence of GOS (patient 
4).  
Cells were pre-treated with 5% ,10% and 15% (v/v) GOS for 2hours and cells were 
incubated with FW for additional 2 hours in a) in the presences of GOS and b) in the 
absence of GOS. Cell viability was measured using MTS assay after the incubation with 
FW. FW did not significantly reduce cell viability (p= > 0.05) in the presence of GOS but 
did decrease cell viability in the absence of GOS. The values are expressed as percentage 
of control, without FW which was used as 100% cell viability. The data represents the 
mean ± SEM of three independent experiments. ****p= < 0.0001, not significant p=>0.05 
ANOVA followed by Tukey's multiple comparisons test. 
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5.3.5.2 12 hours pre-treatment with galactooligosaccharide before FW 
cytotoxicity assay:  
5.3.5.2.1 Type 2 diabetes patient 1 
For sample 1, the result showed that cells pre-treated with B-GOS for 12 
hours , followed by incubation for 2 hours with FW in the presence of B-GOS, 
increased cell viability from 42% of the non-infected control (Figure 5.5 A) to 85%, 
94%, and 157% of the control for 5% , 10% and 15% v/v concentration respectively 
(Figure 5.10 A). Also, incubation in the presences of 15% v/v B-GOS, significantly 
increased cell viability compared to control (p=0.0198), 5% (p=0.0032) and 10% 
(p=0.0092). However, the incubation of cells with FW in the absence of B-GOS 
caused significant decrease in cell viability for B-GOS 5% v/v concentration which 
decreased to 41% of the control (p=0.001) and also compared to 10 (p=0.0001) and 
15% (p=0.007) v/v concentrations significantly decreased cell viability (Figure 
5.10B).  
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Figure 5-10: The effect of FW on cell viability in the prescence or absence of GOS 
(patient 1).  
Cells were pre-treated with 5% ,10% and 15% (v/v) GOS for 12hours and cells were 
incubated with FW for additional 2 hours in a) in the presences of GOS and b) in the 
absence of GOS. Cell viability was measured using MTS assay after the incubation with 
FW. FW did not significantly reduce cell viability (p=> 0.05) in the presence of GOS but 
did decrease cell viability in the absence of GOS only at 5% v/v. The values are 
expressed as percentage of control (without FW) which was used as 100% cell viability. 
The data represents the mean ± SEM of triplicates of three independent experiments. 
***p= < 0.001, **p=<0.01 *p=< 0.05 ANOVA followed by Tukey's multiple comparisons 
test. 
 
5.3.5.2.2 Type 2 diabetes patient 2 
For sample 2, the result showed that cells pre-treated with B-GOS for 12 
hours, followed by incubation for 2 hours with FW in the presence of B-GOS 
decreased cell viability from 83% of the non-infected control (Figure 5. 5B) to 62% 
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and 69%, for 5%, 10%, respectively, while 15% v/v increased cell viability 
compared to the negative control (Figure 5.11A). Also, in the presence of B-GOS, 
15% v/v concentration significantly increased cell viability compared to 5% v/v 
(p=0.0331). However, the incubation of cells with FW in the absence of B-GOS, 
5% (p=0.0367) and 15% (p=0.007) v/v concentrations significantly decreased cell 
viability as it was 69%, and 65% of the positive control, respectively (Figure 5.11 
B).  
 
Figure 5-11: The effect of FW on cell viability in the prescence or absence of GOS 
(patient 2).  
Cells were pre-treated with 5% ,10% and 15% (v/v) GOS for 12hours and cells were 
incubated with FW for additional 2 hours in a) in the presences of GOS and b) in the 
absence of GOS. Cell viability was measured using MTS assay after the incubation with 
FW. FW did not significantly reduce cell viability (p=>0.05) in the presence of GOS but 
did decrease cell viability in the absence of GOS at 5% and 15% v/v. The values are 
expressed as percentage of control, (without FW) which was used as 100% cell viability. 
The data represents the mean ± SEM of triplicates of three independent experiments. 
*p=< 0.05 ANOVA followed by Tukey's multiple comparisons test. 
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5.3.5.2.3 Type 2 diabetes patient 3 
For sample 3, the result showed that cells pre-treated with B-GOS for 12 
hours, followed by incubation for 2 hours with FW and in the presence of B-GOS, 
resulted in increased cell viability from 85% of the non-infected control (Figure 5. 
5C) to 114%, 135%, and 87% of the negative control for 5%, 10% and 15% v/v B-
GOS, respectively (Figure 5.12A). However, the incubation of cells with FW in the 
absence of B-GOS had no significant effect on cell viability (p= >0.05) as it was 
85%, 106% and 106% of the negative control for 5%, 10% and 15% v/v 
concentration, respectively (Figure 5.12B).  
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Figure 5-12: The effect of feacal water on cell viability in the presence or absence of 
GOS (patient 3).  
Cells were pre-treated with 5% ,10% and 15% (v/v) GOS for 12hours and cells were 
incubated with FW for additional 2 hours in a) in the presences of GOS and b) in the 
absence of GOS. Cell viability was measured using MTS assay after the incubation 
with FW. FW did not significantly reduce cell viability in the presence and absence of 
GOS. The values are expressed as percentage of control, (without FW) which was used 
as 100% cell viability. The data represents the mean ± SEM of triplicates of three 
independent experiments. Not significant p=> 0.05 ANOVA followed by Tukey's 
multiple comparisons test. 
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(Figure 5. 5D) to 92%, 117%, and 150% of the negative control for 5%, 10% and 
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15% v/v concentration, respectively (Figure 5.13 A). Also, in the presence of B-
GOS, 15% v/v concentration significantly increased cell viability compared to 
control (p=0.0468) and 5% (p=0.0176) v/v concentration. However, the incubation 
of cells with FW in the absence of B-GOS caused significant decrease in cell 
viability to 51% of the control for 5% (p=0.0010) v/v concentration and 15% v/v 
increased cell viability when compared to the control (p= 0.0248), 5% (p= < 0.001) 
and 10% (p= 0.0004) (Figure 5.13 B). 
 
 
Figure 5-13: The effect of FW on cell viability in the prescence or absence of GOS 
(patient 4).  
Cells were pre-treated with 5%, 10% and 15% (v/v) GOS for 12hours and cells were 
incubated with FW for additional 2 hours in a) in the presences of GOS and b) in the 
absence of GOS. Cell viability was measured using MTS assay after the incubation with 
FW. FW did not significantly reduce cell viability in the presence of GOS but did 
decrease cell viability in the absence of GOS only at 5% v/v. The values are expressed as 
percentage of control, (without FW) which was used as 100% cell viability. The data 
A B 
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represents the mean ± SEM of triplicates of three independent experiments. ****p = < 
0.0001, ***p= < 0.001, *p=< 0.05 ANOVA followed by Tukey's multiple comparisons test. 
5.4 Discussion 
The present investigation found that both pro-inflammatory and anti-
inflammatory cytokines can be measured in-vitro in T2D patients using protein 
extracted from faecal samples. Although all 23 selected cytokines were detected 
in all T2D patients faecal samples (n=4), 12 cytokines were significantly different 
(p= < 0.05) between individual patients. This suggests that faecal samples could 
be used as a non-invasive tool to evaluate cytokines/inflammation profiles in T2D 
patients. However, the cytokines may not have originated from a single site 
rather multiple sites of inflammation, which may or may not have degraded 
before reaching the faeces. The differences observed between patients faecal 
samples in terms of the levels of cytokines present could potentially have 
contributed directly to the cytotoxic effect of the FW samples used in the cell 
viability assay in-vitro. 
Cytokines have been previously measured in faecal samples collected from 
children with inflammatory bowel disease or infective diarrhoea [166] and 
Shigella dysenteriae 1 infection [167], International travellers with diarrhoea due 
to Noroviruses [168], burn patients [169] , and patients with Clostridium difficile 
infections [170] , but to the best of my knowledge no study has been performed on 
human T2D faecal samples. However, to support the results observed in this 
study, several in-vivo inflammatory cytokines measurements in T2D have shown 
that pro-inflammatory cytokines including TNF alpha, IL-6, IL-15, MCP-1 and 
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IL-1beta play a key role in initiating inflammatory responses and insulin 
resistance [159, 171-176]. Chronically elevated levels of TNF alpha and IL6 can 
affect insulin sensitivity by altering different key steps in the insulin signaling 
pathway such as stimulate phosphorylation of serine residue instead of tyrosine 
in insulin receptor substrate-1 (IRS1), leading to inactivation of insulin signaling, 
thereby causing IR [177-180]. Furthermore, hyperglycemia has been shown to 
acutely increase the levels of circulating TNF alpha and IL-6, while IL-6 was 
reported to be increased in women who later developed T2D [181, 182]. Also, TNF 
alpha and IL6 were showed to be increased in T2D women with and without 
cardiovascular diseases [171]. Likewise, TNF alpha and IL6 were significantly 
increased in T2D patients compared to normal subjects [183]. Also a study 
reported that TNF alpha and IL6 concentrations were increased in obese non-
diabetic and diabetic patients with high insulin resistance. Serum concentration 
of TNF alpha and IL6 significantly correlated with BMI. IL6 was proportional to 
insulin resistance and blood glucose. Although TNF alpha remain unchanged in 
obese patients placed on a very low-calorie diet (VLCD) for a 3-week period, IL6 
decreased significantly in both serum and adipose tissue, thereby concluding that 
increased IL6 is associated with severe diabetes [178]. Similar to the above study, 
it was reported that serum pro-inflammatory cytokine IL-6 concentrations but 
not TNF alpha were higher in subjects with impaired glucose tolerance and T2D 
than in the control subjects. The change in IL-6 level seem to also have a relevant 
immune changes because the acute phase proteins C-reactive protein, serum 
amyloid A protein and fibrinogen were also increased. Again the authors 
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concluded that IL-6 associated rather than TNF alpha associated responses were 
unregulated in patients with T2D [184]. All the above studies showed that IL-6 
play a key role in inflammation in T2D, which was also one of the cytokine that 
differed between individual T2D patients in this study. 
The cytokine profiling results follow on to the next series of experiments 
presented in this chapter which determined the cytotoxicity level of all T2D 
patients FW samples and demonstrated how the prebiotic GOS , can protect 
epithelial cells in a Cao-2 model . Initially, the cytotoxicity of the various 
concentration of B-GOS and incubation time used in the experiment were 
investigated. Caco-2 cells were pretreated with B-GOS at 5%, 10% and 15% v/v 
concentration for 2 hours and 12 hours using MTS assay. At these concentrations 
and incubation times, B-GOS had no cytotoxic effect as cell viability was not 
decreased, when compared to the control, rather 5% v/v (p=0.006) for 2 hours and 
5% and 10% v/v for 12 hours post incubation, increased cell viability compared to 
the control (Fig5.4). The next step was to investigate the cytotoxicity of the T2D 
patients FW samples on Caco-2 cells. It was observed that 2 of 4 patients FW 
samples (1 and 4) were cytotoxic to the cell while the other 2 patients FW 
samples (2 and 3) had no cytotoxic effect as cell viability decreased and increased 
respectively. It is worth noting that the 2 T2D patients (1 and 4) FW samples had 
similar cytokine profile with a significantly higher level of IL-6 and IL-13, which 
are known pro-inflammatory cytokines. Also, patient 1 and 4 combined had 
higher pro-inflammatory cytokines such as IL-3, IL-8, IFNg8, and IL-7. These 
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cytokine profile is similar to the inflammatory response that has been previously 
reported in T2D patients measured in-vivo [178, 184]. In addition, all T2D 
patients faecal sample had low level of TNF alpha. Patient 1 had higher level of 
9.5% compared to 7%, 3.5% and 2% for patient 2, 3, and 4 respectively. The 
higher level of TNF alpha in patient 1 maybe the reason for its higher level of IL6 
as TNF alpha has been found to increase the expression of the gene encoding IL6 
and MCP-1 [173, 185]. Also, relating it to the patients measured anthropometric 
parameters a trend was observed. Although no correlation analysis was 
performed, it was observed that the anthropometric characteristic of the 2 T2D 
patients (1 and 4) whose FW samples were cytotoxic , consisted of high body fat 
(39.40% and 31.10%, respectively), fat mass (36.80kg and 17.90kg respectively), 
and low level of total body water (43.10kg and 48.20kg, respectively). While, the 2 
T2D patients (2 and 4) whose FW samples were not cytotoxic had low body fat 
(21.60% and 16.90% respectively), fat mass (17.45kg and 15.25kg) and high level 
of total body water (54.30kg and 58.20kg respectively). Furthermore, the 2 T2D 
patients FW samples were among the FW samples that caused decreased TER 
over a 48 hours period , which significantly associated with elevated level of body 
fat % and decreased level of total body water ( chapter 4, fig 4.2g and h; 4.7 a-d). 
Postulating from these observed trends, there may be a possible link between 
pro-inflammatory cytokines leading to cell death and decreased TER.  
Lastly, the ability of prebiotic, B-GOS to offer either protection or 
preventive effect against the cytotoxicity of T2D FW samples on Caco-2 cells was 
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investigated. Again, cells were pretreated with B-GOS at 5%, 10% and 15% v/v 
concentration for 2 hours and 12 hours before infection with FW samples for 2 
hours. To determine protective or preventive effect, cells were either incubated in 
the presence or absence of B-GOS during a 2 hours incubation with FW samples. 
For 2 hour pretreatment with B-GOS, the cytotoxic FW samples (T2D patients 1 
and 4) (Fig 5.10 and 5.13), B-GOS effect on cells was preventive than protective, 
as the absence of B-GOS resulted in a significant decrease in cell viability 
compared to the control. While the 2 non-cytotoxic FW sample (T2D patient 2 and 
3) (fig 5.11 and 5.12), B-GOS had a protective effect as the absence of B-GOS 
during incubation with FW had no impact on cell viability. For 12 hours 
pretreatment with B-GOS, the absence of B-GOS during infection with FW for 
cells pretreated with 10% and 15% v/v concentration had a protective effect as 
cell viability did not decrease compared to control but at 5% v/v concentration, 
cell viability significantly decreased compared to control , 10% and 15% v/v 
concentration.  
To the best of our knowledge, this is the first study to explore the concept 
of B-GOS protecting epithelial cells in a T2D model of infection in vitro, using FW 
as a complex mixture containing both pro and anti-inflammatory cytokines. 
These data suggest that B-GOS effect on cells against the cytotoxicity of FW may 
be advantageous in a dose and time dependent manner. Higher dose and longer 
pre-incubation time offers protective effect even in the absence of B-GOS during 
infection. Although this study did not measure the level of either the cytokines 
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measured in this study or new pro-inflammatory cytokine produced by the Caco-2 
cells after exposure with GOS and FW, B-GOS protective effect appear quite 
potent to act against a possible increase in pro-inflammatory cytokines released 
by the cells . The study by Vendrig et al., 2013, investigated the effects of three 
different products containing either GOS alone, a combination of GOS with FOS, 
and a triple combination of GOS and FOS with acidic-oligosaccharides (AOS), at 
different concentrations on the LPS induced inflammatory response in equine 
peripheral blood mononuclear cells (PBMCs). The exposed cultured PBMCs to 
either GOS or GOS/FOS fractions resulted in a substantial dose-dependent 
increase of TNF-α production in LPS challenged PBMCs, while incubation with 
GOS/FOS/AOS resulted in a dose-dependent reduction of both TNF-α and 
interleukin-10 production following LPS challenge. Also, incubation with 
GOS/FOS/AOS significantly increased the apparent PBMC viability, indicating a 
protective or mitogenic effect [186]. Similar to the above study, human milk–
derived oligosaccharides and plant-derived oligosaccharides were reported to 
stimulate cytokine production of cord blood T-Cells In vitro [187]. However the 
method of action remains unknown in both studies. 
It may be postulated that the cytotoxic effect of 50% of the FW samples 
used in this study arose from the pro-inflammatory cytokines present in the 
patient’s samples as well as induced production of cytokines by the Caco-2 cells. 
T2D patient 1 and 4 FW samples which were cytotoxic to cells had a similar 
cytokine profile with significantly higher pro-inflammatory cytokines including 
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IL6 which has been implicated in low grade inflammation in T2D [173, 184]. The 
2 non-cytotoxic FW samples (T2D patients 2 and 3) had lower level of IL6 
measured; patient 2 had only 2 pro-inflammatory cytokines that was significantly 
higher compared to other patients and patient 3 had higher level of TGF-beta 1, 
which is an anti-inflammatory cytokine. These profiles may have attributed to 
the non- cytotoxic effect observed in-vitro on cell viability by these FW samples. 
The possible mechanism could be the inactivation of NFKb which is a 
transcription factor that modulates the expression of many inflammatory 
cytokines. The activation of NFKb occurs when pattern-recognition receptors 
activates the NFKb signaling pathways, thus leading to an inflammatory 
cytokines [184, 188]. Also, it can be postulated that the activity of B-GOS on the 
Caco-2 cells may be by acting as pro-proliferation agent by inactivation of NFKb 
thereby preventing cell death, hence increasing the number of viable cells even in 
the presence of FW as this was observed during the experiment when viewed 
using a light microscope (data not shown). This observation is also in agreement 
with the study by Miriam et al. (2015), which observed an increased cell 
proliferation of intestinal epithelial cells as a direct impact of dietary fibers in 
vitro [158].  
In conclusion, this chapter presents an important aspect to the use of FW 
samples of T2D patients as a model of inflammation in T2D, which is quite 
complex but may be a potential way to investigate patients inflammatory state in 
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a non-invasive manner and the mechanism of action is worth investigating in 
future studies.  
 
 
Chapter 6 
 
GENERAL DISCUSSION 
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6. General Discussion 
The experimental work described in this thesis were primarily designed to 
investigate the role of the gut microbiota in human type 2 diabetes. This thesis 
does not follow a sequence, where the result of a study prompted further 
investigation, rather it was a way of exploring the gut microbiota produced 
compounds in an in vitro context to finding possible new ways of understanding 
the host-microbiota interaction.  
However, the results presented in chapter 3, indicated that there were no 
significant difference in the gut microbiota between T2D and healthy controls, 
although the T2D group had higher levels of phylum Proteobacteria, which 
contain more bacteria that are Gram-negatives. Gram-negative bacteria are 
known to have an outer cell membrane containing LPS, which can cause 
inflammation [72, 154, 189]. This lead to the idea that the faecal samples could 
potentially contain compounds from bacteria and host, that maybe different 
between T2D patients and healthy controls, hence can distinguish between 
healthy and diseased state.  
The method of preparation of FW was an important factor to carefully 
consider as it was the experimental medium used in Chapter 4 and 5. It is 
important to note that the method of FW preparation (section 2.6) resulted in a 
very dilute solution (1:40 wt/vol), hence it was used for incubations without 
dilution. This is contrary to the study of Gill et al. (2007), where faecal sample 
 142 
was weighed and mixed with ice cold PBS 1:1 wt/vol ,but in agreement with the 
finding of the study, which was used to determine the effect of FW on colonic 
mucosal barrier function at 0 and 48 hours, TER was affected by samples from 
elderly when compared with young adults. Also a study used the extraction of 
faeces in PBS method of preparation in a 1:1 wt/ vol dilution. But contrary to the 
finding of the study, TER remained unchanged after 24 hours post-incubation. 
Other methods of preparation as observed in several studies was to weigh faecal 
samples, homogenised, centrifuged and either diluted before incubations [132, 
134] or used directly [126, 133]. However, it has been reported that the method of 
preparation does not affect experimental outcomes. A study by Klinder et al. 
(2007), looked at 3 method of FW preparation which were direct centrifugation, 
extraction of faeces in PBS before centrifugation and centrifugation of lyophilised 
and reconstituted faeces. All preparation methods were used to assess 
genotoxicity and 4 out of 7 samples were non-genotoxic irrespective of the FW 
preparation methods, while 2 out of 7 samples were similarly genotoxic when 
using direct centrifugation and extraction of faeces in PBS before centrifugation. 
Also TER was measured at 24 hours for all 3 preparation method and no 
difference was observed for all methods, which had no effect on TER [125]. Since 
extraction of faeces in PBS before centrifugation allows for more FW preparation 
that can be filtered sterilized, stored and used in further experiment, this method 
was considered suitable for use in this thesis.  
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Focused mainly on diet, several studies has explored the activity of FW in-
vitro using colonocyte-based models of cytotoxicity, genotoxicity, and barrier 
function. Also, these studies are mostly in terms of the role in the development 
and progression of colon cancer risk [127, 132, 190, 191] . However, in chapter 4 
of this thesis, FW from T2D was assessed on Caco-2 cell monolayers to evaluate 
the impact on monolayer integrity as an index of paracellular permeability in the 
context of T2D disease. The purpose was to investigate if there was a 
discrimination between healthy and diseased individuals based on FW. TER was 
chosen to be used alone because to continuously monitor the barrier integrity, 
non-invasive techniques are best suited. Also, it is a very sensitive and reliable 
method to confirm the integrity and permeability of the monolayer. Although the 
best indicators of the integrity of the tight junctions and of the cell monolayer are 
measurements of TER and of transepithelial passage of marker molecules, they 
determine different experimental parameters [192-194].  
The result observed in chapter 4 was able to discriminate between healthy 
and diseased state as FW from T2D patients (n=9) had a significant impact on 
TER causing decrease at 24 and 48 hours post incubation when compared to 
healthy controls (n=3). This is in agreement with a study where 2 FW from 
healthy volunteers had no effect on TER after 24 post incubation [125]. Although 
literature search did not produce results for effect of FW from T2D on TER, it 
certainly appears possible given the significant difference observed in this thesis, 
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that the activity of FW from the T2D patients can be a good tool to identify 
diseased state when compared with healthy state.  
In addition, a novel aspect of this thesis (chapter 4) was to identify 
patients, whose T2D have been ‘well managed’ over time and those with possibly 
‘not so well managed state’. Again, literature search produced no result to 
support this aspect of this investigation directly but other in-vitro studies on the 
effect of LPS, TNF alpha and bile acids on barrier function was used to explain 
the findings in this thesis. Patients measurements of in-vivo markers of T2D 
including insulin, total cholesterol, LPS and TNFalpha were correlated with TER 
measurements for 0, 24 and 48 hours post incubation with FW samples (n=5). It 
was observed that there was a relationship between all markers of T2D with TER 
at 0, 24 and 48 hours. It is worth noting that patients with high levels of markers 
of T2D, had FW samples that reduced TER over a 48 hours period. At 48 hours 
post-incubation with FW, 4 out of 5 samples had an increase in TER, except 1 
sample for the patient who had higher level of LPS. LPS is contained in the outer 
membrane of bacteria belonging to the phylum Proteobacteria, which was higher 
in T2D patients when compared to healthy control (chapter 3). These 
observations can be used to postulate that the blood level of these markers of T2D 
can directly or indirectly impact the gut-microbiota, hence the composition of 
faecal samples. This also suggests that T2D management maybe an important 
way of achieving a stable and healthy gut microbiota. Furthermore, the 
relationship between anthropometric parameters of the T2D patients and TER 
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measurements for 0, 24 and 48 hours was assessed. It was observed that high 
body fat (%) and low total body water (kg) were significantly associated with 
decreased TER at 24 and 48 hours. Since the consumption of high fat diet is 
known to favour the growth of pathogenic bacteria in the gut, hence the level of 
endotoxins such as LPS might be on the increase in the gut [71, 72, 74], this may 
possibly address the result observed in this thesis.  
Prebiotic has been shown to be beneficial as it improve various metabolic 
markers in-vivo [93, 157] . However in this thesis, non-prebiotic B-GOS effect on 
cell resistance to FW cytotoxicity was assessed in a time and dose dependent 
manner (chapter 5). Before using the FW from the T2D patients (n=4), the 
cytokine profile of the faecal samples were measured using a cytokine array. This 
was performed because it was thought that the combinations of cytokine present 
in the faecal sample will be different between individual T2D patients, which will 
determine the FW cytotoxicity on Caco-2 cells in-vitro. The results observed 
showed that the cytokine profile of T2D patients with cytotoxic FW were different 
from those patients with non-cytotoxic FW. Again, literature search produced no 
result for studies that could directly be related to the findings here but in-vivo 
studies have shown IL-6, TNF alpha , IFNg, IL-13 as pro-inflammatory cytokines 
present in T2D patients that play a key role in driving inflammation . It is also 
possible that using faecal samples as a non-invasive way to determine the 
inflammatory tone in T2D maybe a good way to determine those with well 
managed T2D. The protective effect of B-GOS against FW cytotoxicity was also 
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observed when B-GOS was present during the incubation with FW samples. 
Contrary to this study, the prebiotic Elixor, a GOS, was found to be less effective 
in increasing the cellular resistance to FW genotoxicity [128] . However, this was 
not the same type of GOS used in this thesis. Also, despite this study was 
performed on cells in-vitro, prebiotic supplementation has been shown to effect 
faecal water genotoxicity in a human study involving 38 healthy male volunteers 
(smokers and non-smokers), after a dietary intervention study with bread 
supplemented with prebiotics (6% inulin) for 5 weeks. Faecal samples were 
collected from volunteers and FW genotoxicity was assayed in human colon HT29 
clone 19A cells. Faecal water genotoxicity was reduced only in non-smokers but 
not in smokers [195]. In addition, prebiotic ameliorated the effect of FW on cells 
in an animal study where rats were administered Azoxymethane (AOM) to 
initiate tumours, treated with inulin/oligofructoses (100g/kg wt/wt) and faeces 
were collected at 0 and 10 days and 2, 4, and 8 months. FW were prepared and 
tested for genotoxicity in HT29 colon cells using the comet assay. Treatment with 
inulin/oligofructoses significantly reduced faecal genotoxicity on cells [191]. These 
studies showed that prebiotic treatment both in-vivo and in-vitro affect the 
activity of FW. However, these studies were not related to T2D or GOS, but 
shows that GOS might also offer non-prebiotic effect independent of the gut-
microbiota. Overall, this thesis work presents possible novel ways to study gut 
microbiota in human T2D in the laboratory in-vitro models and as well linked 
with in-vivo works in T2D.  
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6.1 Study Limitations 
A number of limitations were identified in the studies performed in this 
thesis. Despite the novelty of the studies presented in chapter 4 and 5, the small 
sample size used exhibits pilot characteristics and therefore it will be necessary 
to conduct this in a larger cohort. However, the small sample size enabled the 
required number of biological replicates for the experiments in chapter 4 to be 
performed as the transwells are expensive and cannot be reused. Although the 
idea of using the FW was to explore a way to use it as a complex mixture and 
relate it to in vivo markers, it would have been an added advantage if the 
composition of the FW was measured. Identifying what compounds were 
implicated in the activity of FW from those with supposed ‘well managed T2D’ 
that had not effect on paracellular permeability would be beneficial to know if 
they are diet related or not. Finally, using B-GOS (chapter 5) may suggests that 
other components (such as glucose) may have influenced the observed outcome of 
the experiment. However, commercially available B-GOS are consumed by 
individuals and not pure GOS, hence the method of preparation (vol/vol 
concentrations) was as used in this thesis. Also, GOS was chosen to be used in the 
study (chapter 5) as it was the prebiotic consumed by the participants in the 
intervention studies in chapter 3, but it might be useful to include other 
prebiotics such as inulin and FOS. 
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6.2 Future studies 
Recommendation for future works might be to conduct the studies (chapter 
3, 4, and 5) in a larger cohort to address study and experimental sample power. 
Also addressing the limitations of the studies (Section 6.1) such as measurement 
of FW composition and use more prebiotics can improve the study outcomes. 
Finally, an important aspect will be to investigate the mechanism behind the FW 
effect on cell monolayer and cytotoxicity, which was not done in this thesis as 
follows: 
1. The role of FW in the expression and redistribution of tight junction 
proteins (such as occludin, ZO-1 and claudins), which may explain the 
reason for decrease cell monolayer integrity in Caco-2 cells can be 
performed using fluorescence microscopy (confocal microscopy).  
2. Determine the activation of immune response in Caco-2 cells, which may 
lead to production of inflammatory mediators that can influence the cell 
response to FW. This can be achieved by measuring cytokines in the cell 
culture media and using western blotting experiment to investigate the 
upregulation / downregulation of inflammatory pathways. 
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Appendix A – Publications, presentations and awards 
Publications 
 Camilla Pedersen , Edith Gallagher , Felicity Horton , Richard J. Ellis , 
Umer Z. Ijaz , Huihai Wu , Etana Jaiyeola , Onyinye Diribe , Thibaut 
Duparc , Patrice D. Cani , Glenn R. Gibson , Paul Hinton ,John Wright , 
Roberto La Ragione , and M. Denise Robertson (2016). Host-microbiota 
interactions in human type 2 diabetes following prebiotic fibre 
(galactooligosaccharide) intake. British Journal of Nutrition. 116(11):1869-
1877. doi: 10.1017/S0007114516004086. Epub 2016 Dec 15. 
 Camilla Pedersen, Edith Gallagher, Felicity Horton, Richard Ellis, Umer 
Ijaz, Etana Jaiyeola, Thibaut Duparc, David Russell-Jones, Paul Hinton, 
Patrice Cani, Roberto LaRagione, and Denise Robertson. 
"Enterobacteriales enrichment in type 2 diabetes is associated with 
impaired intestinal permeability”. (Submitted to Clinical Science-Under 
peer review) 
 
Presentations 
 10/2016 Schlumberger Foundation Faculty for the Future Fellows Forum. 
Cambridge, UK. Poster. 
 09/2015 Human Immunity and the Microbiota in Health and Diseases. 
Montreal, Canada. Poster.  
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 06/2015 University of Surrey, Faculty of Health and Medical Sciences 
Research Festival. Guildford, Surrey. Poster. 
 
Awards 
1. Awarded Schlumberger Foundation Faculty for the Future 2016-2017 
Fellowships. 
2. Awarded Schlumberger Foundation Faculty for the Future 2015-2016 
Fellowships. 
3. Travel grant to attend Schlumberger Foundation Faculty for the Future 
Fellows Forum. Cambridge (UK) from October 30th to November 2nd, 
2016. 
4. Travel Grant to attend the Annual meeting of the Society for General 
Microbiology (SCG/15/037). Birmingham, UK (March, 2015). 
5. Awarded Funds for Women Graduates (FfWG) - Emergency Grants. March 
2015 
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Appendix B: Statistically analyzed sequencing data from which mean, p and q-
values were reported in chapter 3. 
 
Table A-1: Statistic data at the phylum level - T2D versus healthy controls 
The phylum Proteobacteria was significant for the P but not Q values. 
Taxon 
Mean 
p-value q-value 
T2D-PRE CON 
Root;Bacteria;Proteobacteria 0.039778662 1.75E-02 0.017780931 0.195590236 
Root;Bacteria;Deferribacteres 0.000100422 0.00E+00 0.317310508 0.887143714 
Root;Bacteria;Fusobacteria 0 1.58E-05 0.317310508 0.887143714 
Root;Bacteria;Bacteroidetes 0.525482539 5.43E-01 0.418616316 0.887143714 
Root;Bacteria;Cyanobacteria 3.77E-05 5.35E-05 0.556057769 0.887143714 
Root;Archaea;Euryarchaeota 0.000140257 1.22E-04 0.59465903 0.887143714 
Root;Bacteria;Verrucomicrobia 0.000663681 1.96E-04 0.596475901 0.887143714 
Root;Bacteria;Other 0.034010269 2.78E-02 0.709857667 0.887143714 
Root;Bacteria;Actinobacteria 0.002829393 1.64E-03 0.775894859 0.887143714 
Root;Bacteria;Firmicutes 0.39695707 0.409425941 0.806494285 0.887143714 
Root;Other;Other 0 0 1 
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Table A-2: Statistic data at the phylum level - T2D subjecs in the prebiotic group 
The phylum Firmicutes was significant for the P and Q values, which was higher 
in the post samples of the prebiotic group. The phylum other bacteria was 
increased in the prebiotic group but not significant. 
 
Table A-3: Statistic data at the phylum level - T2D subjects in the placebo group 
Taxon 
Mean 
p-value q-value 
PRE-
PREBIOTIC 
POST-
PREBIOTIC 
Root;Bacteria;Firmicutes 0.401312683 0.4872494 0.001953125 0.021484375 
Root;Bacteria;Other 0.025627351 0.0449443 0.018554688 0.102050781 
Root;Bacteria;Bacteroidetes 0.515273542 0.4372489 0.053710938 0.196940104 
Root;Bacteria;Proteobacteria 0.051326987 0.0258083 0.083007813 0.228271484 
Root;Archaea;Euryarchaeota 0.000207648 0.0009009 0.285049407 0.581735931 
Root;Other;Other 0 0.0000235 0.317310508 0.581735931 
Root;Bacteria;Actinobacteria 0.00495209 0.0035289 0.444586739 0.687753353 
Root;Bacteria;Verrucomicrobia 0.001062338 0.0001876 0.500184257 0.687753353 
Root;Bacteria;Deferribacteres 2.37E-04 0.0001084 0.654720846 0.800214367 
Root;Bacteria;Cyanobacteria 0 0.0000000 1 1 
Root;Bacteria;Fusobacteria 0 0.0000000 1 1 
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The Phylum Firmicutes was significant for the P but not Q values, and which was 
higher in the post samples of the prebiotic group. 
 
Taxon 
Mean 
p-value q-value 
PRE-PLACEBO POST-PLACEBO 
Root;Bacteria;Firmicutes 0.398943399 5.03E-01 0.020996094 0.230957031 
Root;Bacteria;Actinobacteria 0.001084987 2.08E-03 0.063964844 0.282877604 
Root;Bacteria;Bacteroidetes 0.522093638 4.26E-01 0.077148438 0.282877604 
Root;Bacteria;Cyanobacteria 0 1.13E-04 0.179712495 0.494209361 
Root;Bacteria;Other 0.039926615 2.95E-02 0.266113281 0.585449219 
Root;Bacteria;Verrucomicrobia 0.000292697 0.000211794 0.500184257 0.894670759 
Root;Bacteria;Proteobacteria 0.037545116 3.92E-02 0.569335938 0.894670759 
Root;Archaea;Euryarchaeota 0.000113547 7.57E-05 1 1 
Root;Bacteria;Deferribacteres 0.00E+00 0.00E+00 1 1 
Root;Bacteria;Fusobacteria 0 0.00E+00 1 1 
Root;Other;Other 0 0 1 1 
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Table A-4: Statistic data at the phylum level - T2D subjects pre and post samples 
The phylum Bacteroidetes was significantly higher in the pre samples and this is 
a true representation of the gut microbiota in T2D subjects. Firmicutes were 
decreased in the pre samples. 
Taxon 
Mean 
p-value q-value 
PRE-T2D POST-T2D 
Root;Bacteria;Firmicutes 3.97E-01 0.497212854 0.003248257 0.035730827 
Root;Bacteria;Bacteroidetes 0.525482539 0.427021742 0.007777278 0.042775031 
Root;Other;Other 0 1.03E-05 0.307821472 0.653808328 
Root;Bacteria;Cyanobacteria 3.77E-05 6.04E-05 0.312333123 0.653808328 
Root;Bacteria;Other 0.034010269 3.75E-02 0.394487168 0.653808328 
Root;Archaea;Euryarchaeota 0.000140257 5.45E-04 0.399445255 0.653808328 
Root;Bacteria;Actinobacteria 0.002829393 2.76E-03 0.416059845 0.653808328 
Root;Bacteria;Proteobacteria 3.98E-02 3.45E-02 0.772180313 1 
Root;Bacteria;Verrucomicrobia 0.000663681 2.91E-04 0.942690469 1 
Root;Bacteria;Deferribacteres 0.000100422 4.77E-05 1 1 
Root;Bacteria;Fusobacteria 0.00E+00 0 1 1 
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Table A-5: Statistic data at the phylum level – healthy control subjects’ normal 
weight (NW) and overweight (OW) 
No statistical significant difference between the two groups. 
Taxon 
Mean  
p-value q-value 
CONTROL-NW CONTROL-OW 
Root;Bacteria;Cyanobacteria 9.94E-05 0 0.164914823 1 
Root;Bacteria;Fusobacteria 2.93E-05 0 0.335234414 1 
Root;Bacteria;Firmicutes 0.431212352 0.378728186 0.550177931 1 
Root;Bacteria;Verrucomicrobi
a 0.00017351 0.000205695 0.841493453 1 
Root;Bacteria;Bacteroidetes 0.53129547 5.64E-01 0.867376498 1 
Root;Bacteria;Other 0.027797025 2.85E-02 0.905062742 1 
Root;Bacteria;Proteobacteria 0.007640601 2.70E-02 0.905062742 1 
Root;Archaea;Euryarchaeota 7.91E-05 0.000159434 0.946851439 1 
Root;Bacteria;Actinobacteria 0.001673165 1.68E-03 0.961178326 1 
Root;Bacteria;Deferribacteres 0 0 1 1 
Root;Other;Other 0 0 1 1 
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Table A-6: Statistic data at the phylum level - T2D subjects on- metformin and 
off-metformin.  
No statistical difference between the two groups. 
Taxon 
Mean (PRE) 
p-value q-value 
Metformin non-metformin 
Root;Bacteria;Cyanobacteria 0 1.23E-04 0.123291598 0.996155635 
Root;Bacteria;Other 0.028418338 4.48E-02 0.237670349 0.996155635 
Root;Bacteria;Actinobacteria 0.003381354 1.23E-03 0.488680305 0.996155635 
Root;Bacteria;Firmicutes 0.385202038 4.07E-01 0.514726755 0.996155635 
Root;Bacteria;Deferribactere
s 1.37E-04 0.00E+00 0.516412268 0.996155635 
Root;Bacteria;Proteobacteria 0.040955929 3.21E-02 0.584535207 0.996155635 
Root;Bacteria;Verrucomicro
bia 0.000831295 0.000182635 0.730487521 0.996155635 
Root;Archaea;Euryarchaeota 0.000174198 4.21E-05 0.7311671 0.996155635 
Root;Bacteria;Bacteroidetes 0.540899428 5.15E-01 0.815036429 0.996155635 
Root;Bacteria;Fusobacteria 0 0.00E+00 1 1 
Root;Other;Other 0 0 1 1 
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Table A-7: Statistic data at the class level - T2D subjects (pre) and healthy 
controls.  
The class Gammaproteobacteria and Erysipelotrichi are higher in the T2D 
subjects but not significant reporting the Q values. 
Taxon 
Mean 
p-value q-value 
T2D-PRE CON 
Bacteria;Proteobacteria;Gammapro
teobact-eria 0.032999021 0.01338151 0.028433062 0.480901705 
Bacteria;Firmicutes;Erysipelotrichi 0.016944412 0.012210368 0.048090171 0.480901705 
Bacteria;Proteobacteria;Alphaprote
obacteria 0.000193758 2.55E-04 0.266793889 0.858106655 
Bacteria;Bacteroidetes;Bacteroidete
s 0.491408427 5.19E-01 0.270710129 0.858106655 
Root;Bacteria;Deferribacteres;Defer
ribacteres 0.000100422 0 0.317310508 0.858106655 
Root;Bacteria;Fusobacteria;Fusobac
teria 0 1.58E-05 0.317310508 0.858106655 
Root;Bacteria;Proteobacteria;Epsilo
nproteobacteria 1.52E-05 0 0.317310508 0.858106655 
Root;Bacteria;Firmicutes;Other 0.007105284 0.005589701 0.399768642 0.858106655 
Root;Bacteria;Proteobacteria;Other 0.00032744 0.000416123 0.44235268 0.858106655 
Root;Bacteria;Firmicutes;Clostridia 0.370714017 0.363028668 0.472970147 0.858106655 
 
 173 
Table A-8: Statistic data at the family level - T2D subjects (pre) and healthy 
controls.  
The family Enterobacteriaceae decreased in the post samples of T2D subjects’ on-
metformin but not significant reporting the Q values 
 
. 
 
 
Taxon 
mean_POST-
met 
mean_POST-no 
met p-value q-value 
Root;Bacteria;Firmicutes; 
Peptostreptococcaceae 0.000527568 0.003684141 7.16E-03 0.386899191 
Root;Bacteria;Proteobacteria
; Oxalobacteraceae 7.28429E-05 0.000462838 0.019754768 0.431930127 
Root;Bacteria;Proteobacteria
; Enterobacteriaceae 0.020119165 0.037855348 0.029987081 0.431930127 
Root;Bacteria;Proteobacteria
; Other 0.000320684 0.000580707 0.031994824 0.431930127 
Root;Bacteria;Firmicutes; 
Veillonellaceae 0.017969968 0.049495103 0.047622378 0.514321678 
